A general term for various neoplastic diseases of the lymphoid tissue.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Antibodies produced by a single clone of cells.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
An encapsulated lymphatic organ through which venous blood filters.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see ANTIGENS, CD3).
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Antibodies obtained from a single clone of cells grown in mice or rats.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
The number of LYMPHOCYTES per unit volume of BLOOD.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
Established cell cultures that have the potential to propagate indefinitely.
Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions.
A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2.
Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Glycoproteins found on the membrane or surface of cells.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that are recognized by the immune system and induce an immune reaction.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A cell line derived from cultured tumor cells.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Tumors or cancer of the THYMUS GLAND.
Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.
A DNA-binding protein that represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Functional inactivation of T- or B-lymphocytes rendering them incapable of eliciting an immune response to antigen. This occurs through different mechanisms in the two kinds of lymphocytes and can contribute to SELF TOLERANCE.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein.
Sites on an antigen that interact with specific antibodies.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Reduction in the number of lymphocytes.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Tumors or cancer of the SKIN.
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Elements of limited time intervals, contributing to particular results or situations.
The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Theoretical representations that simulate the behavior or activity of immune system, processes, or phenomena. They include the use of mathematical equations, computers, and other electrical equipment.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
T-cell enhancement of the B-cell response to thymic-dependent antigens.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Tumors or cancer of the EYE.
The major group of transplantation antigens in the mouse.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors.
Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
A proinflammatory cytokine produced primarily by T-LYMPHOCYTES or their precursors. Several subtypes of interleukin-17 have been identified, each of which is a product of a unique gene.
DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the TcR beta genes is essentially the same in all species and is similar to the organization of Ig genes.
Subunits of the antigenic determinant that are most easily recognized by the immune system and thus most influence the specificity of the induced antibody.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Tumors or cancer of the NOSE.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP.
A calcium-dependent pore-forming protein synthesized in cytolytic LYMPHOCYTES and sequestered in secretory granules. Upon immunological reaction between a cytolytic lymphocyte and a target cell, perforin is released at the plasma membrane and polymerizes into transmembrane tubules (forming pores) which lead to death of a target cell.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Transplantation of an individual's own tissue from one site to another site.
The property of the T-CELL RECEPTOR which enables it to react with some antigens and not others. The specificity is derived from the structure of the receptor's variable region which has the ability to recognize certain antigens in conjunction with the MAJOR HISTOCOMPATIBILITY COMPLEX molecule.
The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement.
Substances elaborated by viruses that have antigenic activity.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)
A family of transcription factors characterized by the presence of highly conserved calcineurin- and DNA-binding domains. NFAT proteins are activated in the CYTOPLASM by the calcium-dependent phosphatase CALCINEURIN. They transduce calcium signals to the nucleus where they can interact with TRANSCRIPTION FACTOR AP-1 or NF-KAPPA B and initiate GENETIC TRANSCRIPTION of GENES involved in CELL DIFFERENTIATION and development. NFAT proteins stimulate T-CELL activation through the induction of IMMEDIATE-EARLY GENES such as INTERLEUKIN-2.
Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Molecule composed of the non-covalent association of the T-cell antigen receptor (RECEPTORS, ANTIGEN, T-CELL) with the CD3 complex (ANTIGENS, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
The type species of ARENAVIRUS, part of the Old World Arenaviruses (ARENAVIRUSES, OLD WORLD), producing a silent infection in house and laboratory mice. In humans, infection with LCMV can be inapparent, or can present with an influenza-like illness, a benign aseptic meningitis, or a severe meningoencephalomyelitis. The virus can also infect monkeys, dogs, field mice, guinea pigs, and hamsters, the latter an epidemiologically important host.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A family of serine endopeptidases found in the SECRETORY GRANULES of LEUKOCYTES such as CYTOTOXIC T-LYMPHOCYTES and NATURAL KILLER CELLS. When secreted into the intercellular space granzymes act to eliminate transformed and virus-infected host cells.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).
A cytokine produced by bone marrow stromal cells that promotes the growth of B-LYMPHOCYTE precursors and is co-mitogenic with INTERLEUKIN-2 for mature T-LYMPHOCYTE activation.

T-cell lymphoma in a savanna monkey (Cercopithecus aethiops) probably related to simian T-cell leukemia virus infection. (1/1303)

Lymphoma was seen in an 11-year-old female savanna monkey (Ceropithecus aethiops). The superficial inguinal and visceral lymph nodes were markedly enlarged, and their architecture was completely effaced by neoplastic cells. The neoplastic cells, which were highly pleomorphic, resembled those in adult T-cell lymphoma-leukemia in humans. Ultrastructurally the neoplastic cells were characterized by nuclear irregularity and clustered dense bodies, and almost all cells showed positivity for CD3. The animal had been reared with her family, and her mother and 2 brothers had antibodies reactive to human T-cell leukemia virus. This virus serologically cross-reacts with simian T-cell leukemia virus, which may be the causative agent of the present neoplasm.  (+info)

Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. (2/1303)

A limited number of patients with adult T cell leukemia/lymphoma (ATL) who received autologous stem cell transplantation (ASCT) have been reported. We report here a case of fatal systemic Candida krusei infection in a female patient with ATL undergoing ASCT. All of the eight patients (including seven patients in the literature) with ATL who received ASCT developed relapse of ATL or death due to ASCT complication, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. At present, ASCT appears to provide little benefit for ATL in contrast to that for other types of aggressive non-Hodgkin's lymphoma.  (+info)

Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. (3/1303)

Expression of cytokines in malignant cells represents a novel approach for therapeutic treatment of tumors. Previously, we demonstrated the immunostimulatory effectiveness of interleukin 1alpha (IL-1alpha) gene transfer in experimental fibrosarcoma tumors. Here, we report the antitumor and immunotherapeutic effects of short-term expression of IL-1alpha by malignant T lymphoma cells. Activation in culture of T lymphoma cells with lipopolysaccharide-stimulated macrophages induces the expression of IL-1alpha. The short-term expression of IL-1alpha persists in the malignant T cells for a few days (approximately 3-6 days) after termination of the in vitro activation procedure and, thus, has the potential to stimulate antitumor immune responses in vivo. As an experimental tumor model, we used the RO1 invasive T lymphoma cell line. Upon i.v. inoculation, these cells invade the vertebral column and compress the spinal cord, resulting in hind leg paralysis and death of the mice. Activated RO1 cells, induced to express IL-1alpha in a short-term manner, manifested reduced tumorigenicity: approximately 75% of the mice injected with activated RO1 cells remained tumor free. IL-1 was shown to be essential for the eradication of activated T lymphoma cells because injection of activated RO1 cells together with IL-1-specific inhibitors, i.e., the IL-1 receptor antagonist or the M 20 IL-1 inhibitor, reversed reduced tumorigenicity patterns and led to progressive tumor growth and death of the mice. Furthermore, activated RO1 cells could serve as a treatment by intervening in the growth of violent RO1 cells after tumor take. Thus, when activated RO1 cells were injected 6 or 9 days after the inoculation of violent cells, mortality was significantly reduced. IL-1alpha, in its unique membrane-associated form, in addition to its cytosolic and secreted forms, may represent a focused adjuvant for potentiating antitumor immune responses at low levels of expression, below those that are toxic to the host. Further assessment of the immunotherapeutic potential of short-term expression of IL-1alpha in activated tumor cells may allow its improved application in the treatment of malignancies.  (+info)

Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. (4/1303)

Ectopic expression of decorin in a wide variety of transformed cells results in growth arrest and the inability to generate tumors in nude mice. This process is caused by a decorin-mediated activation of the epidermal growth factor receptor, which leads to a sustained induction of endogenous p21(WAF1/CIP1) (the cyclin-dependent kinase inhibitor p21) and growth arrest. However, mice harboring a targeted disruption of the decorin gene do not develop spontaneous tumors. To test the role of decorin in tumorigenesis, we generated mice lacking both decorin and p53, an established tumor-suppressor gene. Mice lacking both genes showed a faster rate of tumor development and succumbed almost uniformly to thymic lymphomas within 6 months [mean survival age (T50) approximately 4 months]. Mice harboring one decorin allele and no p53 gene developed the same spectrum of tumors as the double knockout animals, but had a survival rate similar to the p53 null animals (T50 approximately 6 months). Ectopic expression of decorin in thymic lymphoma cells isolated from double mutant animals markedly suppressed their colony-forming ability. When these lymphoma cells were cocultured with fibroblasts derived from either wild-type or decorin null embryos, the cells grew faster in the absence of decorin. Moreover, exogenous decorin proteoglycan or its protein core significantly retarded their growth in vitro. These results indicate that the lack of decorin is permissive for lymphoma tumorigenesis in a mouse model predisposed to cancer and suggest that germ-line mutations in decorin and p53 may cooperate in the transformation of lymphocytes and ultimately lead to a more aggressive phenotype by shortening the tumor latency.  (+info)

Molecular analysis of 1p32 genetic involvement in pediatric T-cell non-Hodgkin's lymphoma. (5/1303)

BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic T-cell non-Hodgkin's lymphoma (T-NHL) are closely related disorders, and distinguishing between the two may be difficult. Cytogenetic investigations of large NHL series reported different recurring chromosomal alterations. Among these, aberrations of chromosome 1p seem to be associated with T-cell differentiation, the region most frequently involved in breakpoints being band 1p32-36. Deletions and translocations involving the same chromosomal region are frequently observed in T-ALL, in which one of the most common genetic changes is the breakage of the TAL1 gene, mapped to the 1p32 chromosomal region. The objective of this study was to assess the possibility of TAL1 involvement also in T-NHL. DESIGN AND METHODS: A series of 17 pediatric T-NHL patients was molecularly characterized by microsatellite markers analysis and by TAL1 gene microdeletions. RESULTS: TAL1 gene rearrangement was found in one case, while loss of heterozygosity (LOH) and microsatellite instability (MI) was identified in another case. INTERPRETATION AND CONCLUSIONS: Overall our findings indicate that, differently from T-ALL, neither TAL1 gene involvement nor LOH or MI at 1p32 appear particularly relevant in the oncogenic process of T-NHL transformation.  (+info)

Microdomain-dependent regulation of Lck and Fyn protein-tyrosine kinases in T lymphocyte plasma membranes. (6/1303)

Src family protein-tyrosine kinases are implicated in signaling via glycosylphosphatidylinositol (GPI)-anchored receptors. Both kinds of molecules reside in opposite leaflets of the same sphingolipid-enriched microdomains in the lymphocyte plasma membrane without making direct contact. Under detergent-free conditions, we isolated a GPI-enriched plasma membrane fraction, also containing transmembrane proteins, selectively associated with sphingolipid microdomains. Nonionic detergents released the transmembrane proteins, yielding core sphingolipid microdomains, limited amounts of which could also be obtained by detergent-free subcellular fractionation. Protein-tyrosine kinase activity in membranes containing both GPI-anchored and transmembrane proteins was much lower than in core sphingolipid microdomains but was strongly reactivated by nonionic detergents. The inhibitory mechanism acting on Lck and Fyn kinases in these membranes was independent of the protein-tyrosine phosphatase CD45 and was characterized as a mixed, noncompetitive one. We propose that in lymphocyte plasma membranes, Lck and Fyn kinases exhibit optimal activity when juxtaposed to the GPI- and sphingolipid-enriched core microdomains but encounter inhibitory conditions in surrounding membrane areas that are rich in glycerophospholipids and contain additional transmembrane proteins.  (+info)

Primary gastric T-cell lymphomas: report of two cases and a review of the literature. (7/1303)

To understand more fully the clinicopathological features of primary gastric T-cell lymphomas (PGTL), we report two cases of PGTL and review the literature. The present cases were not associated with human T-cell leukemia virus type 1 (HTLV-1) and were at clinical stage IIE. In both cases, T-cell origin of the lymphoma cells was diagnosed immunohistochemically. The clinical courses of these two cases were different: one followed a very aggressive clinical course and the patient died 6 months after the diagnosis, whereas the other patient survived more than 2 years without adjuvant chemotherapy. Clinicopathological features of 23 patients with PGTL are summarized with regard to their differences from primary small intestinal T-cell lymphomas (PSITL) and by association with HTLV-1. The median age at onset of PGTL was 58 years. The gender ratio was male-dominant (M:F = 2.3:1). About two-thirds (10 of 17) of PGTL cases had evidence of HTLV-1 infection. The most common presenting symptom for PGTL was upper abdominal discomfort and/or pain (76%), whereas that in PSITL was weight loss (61%) and diarrhea (42%). Typical lesions for PGTL were large ulcerations at the corpus to antrum. Neoplastic cells had no typical morphological characteristics for PGTL including HTLV-1-associated cases. CD3+4+8- was the most frequently observed surface phenotype of PGTL cells. Laboratory findings at diagnosis were not informative. Most patients were treated by gastrectomy with or without chemotherapy. PGTL, excluding that with HTLV-1, showed better prognosis than PSITL, although PGTL with HTLV-1 had a poorer prognosis.  (+info)

Mouse p73 gene maps to the distal part of chromosome 4 and might be involved in the progression of gamma-radiation-induced T-cell lymphomas. (8/1303)

We have isolated and sequenced a DNA fragment of about 12 kb that comprises exons 5-14 of the mouse p73 gene. We have identified four polymorphic markers, and one of them has been used to genetically map p73 to the distal part of chromosome 4. Previously, we have reported that gamma-radiation-induced T-cell lymphomas undergo frequent loss of heterozygosity around marker D4Mit205b at the distal part of chromosome 4. Based on this, we have performed loss of heterozygosity analysis in a set of T-cell lymphomas, and we have found allelic losses of p73 in 32.6% (16 of 49) of the tumors analyzed. Interestingly, allelic losses occur concurrently at both p73 and D4Mit205b, thus suggesting that p73 could be specifically inactivated in radiation-induced T-cell lymphomas.  (+info)

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare subtype of intestinal T-cell lymphoma that occurs mostly in Asia. CHOP-like therap
Background Previously, wed shown that persons infected with human T-cell lymphoma leukemia virus 1 or 2 2 (HTLV-1 or 2) had an increased prevalence of antibodies to a peptide in the Pol protein of the retrovirus HERV-K10, homologous to a peptide in HTLV gp21 envelope protein. HTLV myelopathy individuals experienced a statistically significant improved prevalence of antibodies to both HERV-K10 peptides (87.5%) vs. the VBD (0%), LGLL individuals (0%), MS individuals (4.8%), and the HTLV positive non-myelopathy topics (5.2%). Bottom line The data claim that immuno-cross-reactivity to HERV-K10 peptides and/or transactivation of HERV-K10 appearance with the HTLV Taxes proteins could be mixed up in pathogenesis of HTLV-associated myelopathy/tropical spastic paraparesis and spastic ataxia. Launch Furthermore to leading to T-cell malignancies, both individual T-cell lymphoma/leukemia infections 1 and 2 (HTLV-1 and HTLV-2) are recognized to trigger myelopathy (HAM) within a minority of contaminated ...
T-cell lymphoma is a cancer that starts in T-cells. T-cell lymphoma can be divided into four classes: extranodal T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma.. In terms of the symptoms of adult T-cell lymphoma, they include:. ...
Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua Ne
TY - JOUR. T1 - Hepatosplenic and other γδ T-cell lymphomas. AU - Vega, Francisco. AU - Medeiros, L. Jeffrey. AU - Gaulard, Philippe. PY - 2007/6/1. Y1 - 2007/6/1. N2 - The 2005 Society for Hematopathology/European Association for Haematopathology Workshop session 11 was dedicated to hepatosplenic T-cell lymphoma (HSTCL). HSTCL is a rare aggressive type of extranodal lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and peripheral blood cytopenias. HSTCL exhibits a distinctive pattern of infiltration; tumor cells preferentially infiltrate the sinusoids of the splenic red pulp, liver, and bone marrow. The tumor cells have a nonactivated cytotoxic T-cell immunophenotype and frequently carry a recurrent cytogenetic abnormality, isochromosome 7q. Most cases express the γδ T-cell receptor, but cases can have an αβ phenotype and are considered to be a variant of the disease. Although HSTCL is the prototype peripheral T-cell lymphoma expressing the γδ T-cell receptor, ...
Localized T-cell lymphoma in the orbit should be treated carefully with planned local radiation plus systemic chemotherapy. However, prognosis is poor once dissemination occurs, and long-term remissions, even with aggressive chemotherapy, are rare.11 Saga et al2 reported two patients with peripheral T-cell lymphoma involving the orbit secondarily from the testicular lymphoma. The patients received chemotherapy and local radiation, but died of progression of the disease. Leidenix et al7 reported the case of primary T-cell lymphoma confined to the orbit in a pediatric patient. The patient received surgical excision, systemic chemotherapy, and local radiation and died of dissemination of the disease. Hassan and Elner6 reported orbital peripheral T-cell lymphoma in a child who responded to local radiation and systemic chemotherapy. T-cell lymphoma is generally rapidly progressive and likely to have a high mortality despite aggressive treatment ...
Primary malignant lymphoma of the urinary bladder is very rare. Less than 100 cases have been reported; most are B-cell lymphomas. We report a case of primary T-cell lymphoma of the urinary bladder in a patient with a history of schistosomiasis. The patient is a 52-year-old man with suprapubic pain …
The molecular alterations involved in the development of T-cell lymphomas are largely unknown. Expression profiling studies in tumors could be considered as the first step for a molecular diagnosis of cancer, allowing a better subclassification of tumors, identification of undiscovered oncogenic pathways, or prediction of outcome (9, 10, 11, 12 , 29) . Microarray experiments on T-cell malignancies, however, have only been carried out for T-cell acute lymphoblastic leukemias (12) along with some studies on expression profiling using cell lines derived from T-cell malignancies (14, 15, 16) , but expression profiling of primary T-cell lymphomas has only been explored for specific subtypes (13) .. The results reported here show the general expression patterns of T-cell lymphomas. The gene expression of these tumors was compared with normal T-lymphocytes and normal lymph node samples to extract those relevant genes characterizing the tumors. Clustering analysis of tumoral samples easily identify the ...
Cytotoxic lymphocytes, including NK cells and cytotoxic T lymphocytes (CTLs), play a major role in the defense against neoplastic processes and viral infections (1). Granule exocytosis is the mechanism by which cytotoxic lymphocytes may induce lysis of its target. This involves granule-associated cytotoxic proteins, including the T-cell intracellular antigen-1 (TIA-1), perforin and granzyme B (1,2). Perforin produces pores that allow the entry of other cytotoxic proteins such as TIA-1 and granzymes, which trigger a process leading to DNA fragmentation and apoptosis of the target cells (1). However, there is evidence that granzyme B may kill targets independently of perforin (2). Recent studies (3,4,5) have demonstrated that the expression of granzyme B by immunohistochemistry in several entities of extranodal peripheral T cell lymphoma (PTCL) and NK cell lymphomas, including nasal and nasal-type NK/T cell lymphomas, hepatosplenic and non-hepatosplenic PTCL, enteropathy-type (ETCL) and non-ETCL
Diagnosis and chemotherapy of aggressive T-cell lymphoma (costs for program #254369) ✔ University Hospital Frankfurt ✔ Department of Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology ✔ BookingHealth.com
Diagnostics and chemotherapy of aggressive T-cell lymphoma (costs for program #243273) ✔ University Hospital Hamburg-Eppendorf ✔ Department of Pediatric Hematology and Oncology ✔ BookingHealth.com
Antengene announced today that NMPA has approved the clinical trial application of ATG-010 for relapsed or refractory peripheral T and NK/T-cell lymphoma on January 13, 2020. This is a single-arm, open-label, multi-center phase Ib clinical trial to evaluate the safety and preliminary efficacy of ...
TY - JOUR. T1 - Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and Monotypic Small CD8-Positive Subsets of Uncertain Significance. AU - Shi, Min. AU - Jevremovic, Dragan. AU - Otteson, Gregory E.. AU - Timm, Michael M.. AU - Olteanu, Horatiu. AU - Horna, Pedro. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The diagnosis of T-cell neoplasms is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. The description of an antibody specific for one of two mutually exclusive T-cell receptor (TCR) β-chain constant regions (TRBC1) provide an opportunity to facilitate the detection of clonal TCRαβ T-cells based on TRBC-restriction. Methods: Twenty patients with mature T-cell neoplasms and 44 patients without evidence of T-cell neoplasia were studied. Peripheral blood (51), bone marrow (10), and lymph node (3) specimens were evaluated by 9-color flow ...
CD20-positive T-cell lymphoma is extremely rare and only two cases of CD20-positive NK/T-cell lymphoma with aggressive clinical courses have been described in the literature. We present a case of unus
Looking for small lymphocytic T-cell lymphoma? Find out information about small lymphocytic T-cell lymphoma. a cancer of the tissue of the lymphatic system lymphatic system , network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the... Explanation of small lymphocytic T-cell lymphoma
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Nasal T/NK-cell lymphomas are highly associated with Epstein-Barr virus (EBV). They are more frequent in Asia than in Western countries. In Central and South America there are few studies about nasal T/NK-cell lymphoma and they have shown a strong predominance of this phenotype in Native American descents, supporting the hypothesis of a racial predisposition for the disease. We studied the lymphomas involving midline facial region at a Brazilian institution. T/NK cell lymphomas (16/25) were more frequently found compared to B lymphomas (9 cases, all B large cell). T/NK cell lymphomas involved predominantly the nasal region. Histologically they showed angioinvasion and necrosis. All of them were positive for CD3 and CD56 and showed numerous tumor cells labeled by EBER-1. Although disease was localized in 61% at diagnosis, there was no tendency to cure. The racial distribution of patients with T/NK-cell phenotype was similar to that found in B-cell lymphomas. EBV was more frequently found in ...
We present that L5178Y murine T-cell lymphoma cells can prime naïve murine macrophages (Mϕ) to subsequent LPS stimulation, resulting in antitumor effects in vitro against L5178Y cells. Priming occurred in both cell-type and TLR specific manner, as L5178Y tumor cells (TC), but not naïve splenocytes, primed Mϕ to ligation of TLR4 but not TLR9. L5178Y-primed Mϕ also showed down-regulation of CD40 and CD86 and up-regulation of B7H1, with no changes of TLR4, B7H4, NKG2D and MHC-II expression. Among different TC lines, the priming effect was limited to murine TC of T cell (L5178Y and YAC-1) but not B cell (A20) or nonmyeloid (B16) origin. Human TC lines including Jurkat (T cell), Daudi (B cell), and M21 (melanoma) failed to substantially prime Mϕ. Neither L5178Y-conditioned supernatants nor co-culture of Mϕ and L5178Y TC in transwells resulted in priming, indicating that direct L5178Y TC-Mϕ contact was needed. Furthermore, TLR4-ligation must not precede contact with L5178Y TC in order to ...
A case of a nasal-type NK/T cell lymphoma of the orbit with distant metastases is reported. The orbital lymphoma was angiodestructive with prominent necrosis and frequent... ...
Despite the recent availability of several new drugs in hemato-oncology, T-cell lymphomas are still incurable and PD-1 blockade could represent a therapeutic chance for selected patients affected by these malignancies, although further studies are required to understand the biological effects of anti-PD-1 mAbs on neoplastic T-cells and to identify biomarkers for predicting and/or monitoring patients response to therapy. Sezary Syndrome (SS) represents a rare and aggressive variant of cutaneous T cell lymphoma (CTCL) with a life expectancy of less than 5 years, characterized by the co-presence of neoplastic lymphocytes mainly in the blood, lymph nodes and skin. In this study we analyzed longitudinal blood samples and lesional skin biopsies of a patient concurrently affected by SS and melanoma who underwent 22 nivolumab administrations. In blood, we observed a progressive reduction of SS cell number and a raise in the percentage of normal CD4+ and CD8+ T cells and NK cells over total leukocytes. Eight
There are different forms of lymphoma, and the causes and risk factors are divers. Lymphocytes are cells of the immune system; that is, they are part of the white blood cells. They are produced by the bone marrow, spleen, thymus and lymph nodes. There are classified in two groups: B cells, whichsecrete antibodies; and T cells, which play the role of natural defense of the body to attack pathogens, microorganisms for instance, directly. T-cell Lymphoma occurs when the T cells begin tomultiply uncontrollably without dying by natural programmed cell-death(PCD), apoptosis.. Common risk factors of T-celllymphoma include: Age - T-cell lymphoma can occur at any age, from early adulthood to old age.. Gender - The cancer is slightly more common in men than in women.. Location - T-cell lymphoma is diagnosed mostly in people of southern Japan, central Africa and the Caribbean, although some irregularcases are occasionallydiagnosed in some other parts of the world.. Viral Infection- the cancer are diagnosed ...
BioAssay record AID 288982 submitted by ChEMBL: Inhibition of P-glycoprotein in MDR mouse T lymphoma cells using rhodamine 123 assessed as ratio of fluorescent uptake relative to untreated control at 1 uM in MDR reversal assay by flow cytometry.
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse from T-cell lymphoma. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.
Here is a presentation on T-Cell Lymphomas that occurred at the North American Educational Forum on Lymphoma in California in November, 2012. The presenter is Dr. Andrei Shustov of the Fred Hutchinson Cancer Research Center in Seattle. The audience was a patient group, so some of the information is quite basic. However, there is considerable detail regarding the rarity of T-Cell Lymphomas, the difficulty in diagnosing them, as well as treatment philosophy and recent developments, to include
Clinical trial for t cell lymphoma | T-Cell Lymphoma | Lymphoma | Non-Hodgkins Lymphoma , Allo-HSCT as First-line Consolidation in High-risk PTCL
Definition of Adult T-cell lymphoma with photos and pictures, translations, sample usage, and additional links for more information.
TY - JOUR. T1 - Prevalence of HTLV-I-associated T-cell lymphoma. AU - Poiesz, B. J.. AU - Papsidero, L. D.. AU - Ehrlich, G.. AU - Sherman, M.. AU - Dube, S.. AU - Poiesz, M.. AU - Dillon, K.. AU - Ruscetti, F. W.. AU - Slamon, D.. AU - Fang, C.. AU - Williams, A.. AU - Duggan, D.. AU - Glaser, J.. AU - Gottlieb, A.. AU - Goldberg, J.. AU - Ratner, L.. AU - Phillips, P.. AU - Han, T.. AU - Friedman-Kien, A.. AU - Siegal, F.. AU - Rai, K.. AU - Sawitsky, A.. AU - Sheremata, William. AU - Dosik, H.. AU - Cunningham, C.. AU - Montagna, R.. PY - 2001/1/3. Y1 - 2001/1/3. N2 - In order to assess the prevalence rate of HTLV-I-associated T-cell lymphomas and human retrovirus infection in general, approximately 21,000 individuals representing various patient populations, retroviral risk groups, and blood donors were examined for HTLV-I, HTLV-II, HIV-1, or HIV-2 infection using serologic and PCR assays. The prevalence rates among volunteer blood donors were 0.02% and 0% for HTLV and HIV, respectively. ...
The Leukaemia Foundation welcomes the Federal Governments announcement that the cancer medicine pralatrexate, sold under the name Folotyn, will be added to Pharmaceutical Benefits Scheme (PBS) from 1 April 2018.. Folotyn is used to treat patients aged 18 years or older with peripheral T-cell lymphoma (PTCL) after previous treatments have not worked or have stopped working.. PTCL is a rare type of non-Hodgkin lymphoma a cancer of the lymphatic system. It develops from mature T-cells, a type of white blood cell that play a central role in the immune response of the body. PTCL may be found in the lymph nodes, skin, bone marrow, liver, or spleen.. Leukaemia Foundation CEO Bill Petch says the announcement is an important step to ensure all Australians living with PTCL have access to the treatment they need.. This listing will make a substantial difference. It means that Australians with PTCL who have run out of treatment options can access this treatment which is showing remarkable results. We are ...
TK1 is a T-cell lymphoma cell line originated by E. C. Butcher and I. L. Weissman from a spontaneous thymic lymphoma/leukemia that developed in an AKR/Cum mouse.   Ref
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.. See Malignant Lymphoma, Guideline for Bone Marrow Staging Studies in Special Instructions.. Depending on the lymphoma subtype suspected, the most appropriate probes to order are listed in Clinical Information.. If the patient is being tracked for known abnormalities, indicate which probes should be used.. Panel includes testing for the following abnormalities using the probes listed:. 14q32.1 rearrangement, TCL1A. -7/7q-/i(7q), D7S486/D7Z1. +8, D8Z2/MYC. This assay detects chromosome abnormalities observed in the blood and bone marrow of patients with T-cell lymphoma. For testing paraffin-embedded tissue samples from patients with T-cell ...
Lymphoma, T-Cell; T-Cell Lymphoma. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
A recent study examined the varying survival rates among US racial/ethnic patient groups with peripheral T-cell lymphoma subtypes.
The US Food and Drug Administration (FDA) has approved Beleodaq (belinostat) for people with peripheral T-cell lymphoma who did not get better after treatment with other drugs, or whose cancer came back after treatment with other drugs.
CHOP chemotherapy (cyclophosphamide, doxorubicin and vincristine chemotherapy with the steroid prednisolone) is the standard treatment for T-cell lymphoma. However, some people do not respond well to CHOP and alternative treatments are needed.
Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.
NEW YORK (Reuters Health) - Patients who have undergone prior systemic therapies for cutaneous T-cell lymphoma may respond well to treatment with romidepsin, a potent inhibitor of histone deacetylases, according to the results of a multicenter, open-label phase II study. Dr. Sean Whittaker of St. Thomas Hospital, London, UK and colleagues...
Immunogen was an epitope that maps to a region between residues 1550 and the C-terminus (residue 1591) of human T-cell lymphoma invasion and metastasis 1 using the numbering given in entry NP_003244.1 (GeneID 7074) (ZFIN Staff ...
T-cells are very important members of the immune system and their three main roles are to help other parts of the immune system to do their job, to directly kill infections/cancers in the body and also to regulate the immune system so as to not attack itself. Sadly, T-cells can be develop cancer themselves and they can be difficult to treat. CPI-818 is a new tablet treatment which targets the internal machinery of the cancerous T-cell. In Western Australia the first patients in the world are being treated with this medicine and people who are eligible for this clinical trial are those with T-cell lymphoma which has persisted or come back after two different combinations of chemotherapy. ...
Maybaum, J; Ullman, B; Mandel, H G.; Day, J L.; and Sadee, D W., In mouse t-lymphoma (s-49) cells. (1980). Subject Strain Bibliography 1980. 581 ...
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who
It is a type I transmembrane protein present on activated T cells, activated B cells, some thymocytes, myeloid precursors, and oligodendrocytes. Though IL2RA has been used as a marker to identify CD4+FoxP3+ regulatory T cells in mice, it has been found that a large proportion of resting memory T cells constitutively express IL2RA in humans.[3] IL2RA is expressed in most B-cell neoplasms, some acute nonlymphocytic leukemias, neuroblastomas, mastocytosis and tumor infiltrating lymphocytes. It functions as the receptor for HTLV-1 and is consequently expressed on neoplastic cells in adult T cell lymphoma/leukemia. Its soluble form, called sIL-2R may be elevated in these diseases and is occasionally used to track disease progression. ...
T-cell lymphoma T-cell lymphomaClassification & external resources MeSH D016399 T-cell lymphoma describes several different types of Non-Hodgkin lymphoma which
Background Bcl-2 (B cell lymphoma/leukemia gene-2) may be the 1st proto-oncogene proven to function by inhibiting programmed cell loss of life/apoptosis. immunofluoresence and blot staining were employed to testify the marker protein of both mesenchymal and epithelial cells. Outcomes Unexpectedly, a dramatic modification of phenotype from epithelial cells to fibroblast-like cells was seen in Bcl-2-transfected cells. Traditional western blot immunofluoresence and evaluation MS-275 staining outcomes proven how the E-cadherin and desmoplakin, markers of epithelial cells, had MS-275 been downregulated in the Bcl-2-transfected cells. Nevertheless, Vimentin and N-cadherin, markers of mesenchymal cells, had been upregulated in these cells. Redistributions of cytokeratin and beta-catenin were seen in the Bcl-2-transfected cells also. Our outcomes demonstrated how the Bcl-2-transfected MCF10ATG3B cells maintained some epithelial markers additional, such as for example epithelial particular antigen (ESA) ...
A novel full-length cDNA was isolated from a murine T-cell lymphoma library that has an open reading frame encoding 381 amino acids. The predicted protein (termed SLY) contains a Src homology 3 domain and a sterile alpha motif, suggesting that it functions as a signaling adaptor protein in lymphocyt …
Hyper-activated STAT5B variants are high value oncology targets for pharmacologic intervention. STAT5B(N642H), a frequently-occurring oncogenic driver mutation, promotes aggressive T-cell leukemia/lymphoma in patient carriers, although the molecular origins remain unclear. Herein, we emphasize the aggressive nature of STAT5B(N642H) in driving T-cell neoplasia upon hematopoietic expression in transgenic mice, revealing evidence of multiple T-cell subset organ infiltration. Notably, we demonstrate STAT5B(N642H)-driven transformation of gammadelta T-cells in in vivo syngeneic transplant models, comparable to STAT5B(N642H) patient gammadelta T-cell entities. Importantly, we present human STAT5B and STAT5B(N642H) crystal structures, which propose alternative mutation-mediated SH2 domain conformations. Our biophysical data suggests STAT5B(N642H) can adopt a hyper-activated and hyper-inactivated state with resistance to dephosphorylation. MD simulations support sustained interchain cross-domain ...
T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the patients recieved classic CHOP regimen(cyclophosphamide,vincr
Nasal T cell lymphoma (published in 2008), Authors: Antonio Cuneo, Francesco Cavazzini, Gian Matteo Rigolin. Published in: Atlas Genet Cytogenet Oncol Haematol.
Enteropathy-associated T-cell lymphoma (EATL), also enteropathy-type T-cell lymphoma (ETTL), is a type of T-cell lymphoma that affects the small intestine. It is the most common primary gastrointestinal T-cell lymphoma, arising from the T cells that are found between the cells that line the small intestinal (brush border cells or small intestinal epithelial cells). These cancerous T-cells are a possible consequence of refractory cases of coeliac disease or in chronic, untreated cases in genetically susceptible individuals. EATL can be classified as an extranodal peripheral T cell lymphoma, a category it shares with hepatosplenic T cell lymphoma and panniculitic T cell lymphoma. It can be further classified in type I and II EATL. Enteropathy associated T-cell lymphoma (EATL) is environmentally induced as a result of the consumption of Triticeae glutens (e.g. wheat gluten). In gluten-sensitive individuals with EATL, 68% are homozygotes of the DQB1*02 subtype at the HLA-DQB1 locus. (See Coeliac ...
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression induces a crosstalk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, using triple immunofluorescence to identify protein coexpression in well-characterized lymphoma cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time PCR, we assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were coexpressed. BCL2 was expressed only in neoangiogenic CD34(+)CD105(+) endothelial cells. In laser-microdissected
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma (PTCL) that accounts for approximately 20% of all T-cell lymphomas. Although recurrent mutations in TET2, IDH2, and DNMT3A that are common in other hematologic malignancies have been identified in AITL, the molecular mechanisms that specifically promote AITL development are unknown. Sakata-Yanagimoto and colleagues performed whole-exome sequencing on 6 AITL samples and identified a recurrent RHOA G17V mutation in 3 AITL samples. Targeted RHOA sequencing in an extended AITL cohort identified RHOA G17V mutations in 49 of 72 (68%) AITLs. Similarly, Palomero and colleagues analyzed the exomes of 12 PTCL cases and identified recurrent RHOA G17V mutations in 22 of 35 (67%) AITLs. No RHOA G17V mutations were identified in other hematologic malignancies other than in a subset of PTCL not otherwise specified that shared AITL features, suggesting that somatic RHOA mutations are a specific feature of AITL. Of ...
Primary cutaneous, extranodal natural killer/T-cell lymphoma, nasal type (PC-ENKTL), is a rare Epstein-Barr virus (EBV)-associated neoplasm with poorly defined clinicopathologic features. We performed a multinational retrospective study of PC-ENKTL and CD56-positive EBV-negative peripheral T-cell ly
Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as angioimmunoblastic lymphadenopathy with dysproteinemia) is a mature T-cell lymphoma of blood or lymph vessel immunoblasts characterized by a polymorphous lymph node infiltrate showing a marked increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) and systemic involvement. Patients with this disease usually present at an advanced stage and show systemic involvement. The clinical findings typically include a pruritic skin rash and possibly edema, ascites, pleural effusions, and arthritis. Due to the systemic nature of this disease, neoplastic cells can be found in lymph nodes, liver, spleen, skin, and bone marrow. This disease was originally thought to be a premalignant condition, termed angioimmunoblastic lymphadenopathy, and this atypical reactive lymphadenopathy carried a risk for transformation into a lymphoma. Currently, it is postulated that the originating cell for this ...
TY - JOUR. T1 - Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. AU - Lee, Hoon K.. AU - Wilder, Richard B.. AU - Jones, Dan. AU - Ha, Chul S. AU - Pro, Barbara. AU - Rodriguez, Maria A.. AU - Romaguera, Jorge E.. AU - Cabanillas, Fernando. AU - Rodriguez, Jose. AU - Cox, James D.. PY - 2002. Y1 - 2002. N2 - There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = ...
Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia Adult Hepatocellular Carcinoma Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult Solid Neoplasm Adult T Acute Lymphoblastic Leukemia Advanced Adult Hepatocellular Carcinoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Cutaneous B-Cell Non-Hodgkin Lymphoma Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Localized Non-Resectable Adult Liver Carcinoma Localized Resectable Adult Liver Carcinoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Progressive Hairy Cell Leukemia Initial Treatment Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma ...
Thank you very much for your kind words. T-Cell Lymphomas are so rare, so aggressive, and so difficult to treat, that I try to reposnd quickly when I see another case. My doctor is Dr. Andrei Shustov at Seattle Cancer Care Alliance, which is the treatment arm of Fred Hutchinson. In conjunction with his peers, he formulated the regimen that, against odds, placed me initially in full response. Not completely unexpected was that some cells survived, demonstrating that the variety I had was highly resistant to all chemotherapy. He also researched and offered me the clinical trial in which I yet participate in the long-term study. Your doctor could certainly consult with him regarding your husbands options as, with all T-Cell Lymphomas, a second opinion on both diagnosis and treatment is a very good idea. I rather doubt that Health Canada would pay for any portion of US treatment. Are there any clinical trials for AITL (or any T-Cell Lymphoma) in Canada? It is good to have a plan B in reserve, as ...
Thank you very much for your kind words. T-Cell Lymphomas are so rare, so aggressive, and so difficult to treat, that I try to reposnd quickly when I see another case. My doctor is Dr. Andrei Shustov at Seattle Cancer Care Alliance, which is the treatment arm of Fred Hutchinson. In conjunction with his peers, he formulated the regimen that, against odds, placed me initially in full response. Not completely unexpected was that some cells survived, demonstrating that the variety I had was highly resistant to all chemotherapy. He also researched and offered me the clinical trial in which I yet participate in the long-term study. Your doctor could certainly consult with him regarding your husbands options as, with all T-Cell Lymphomas, a second opinion on both diagnosis and treatment is a very good idea. I rather doubt that Health Canada would pay for any portion of US treatment. Are there any clinical trials for AITL (or any T-Cell Lymphoma) in Canada? It is good to have a plan B in reserve, as ...
Dr. Assanie-Shivjis Ph.D thesis work was carried out under the supervision of Dr. Shahid Pervez, Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan. She studied immunological aspects of 99 T-cell Non-Hodgkins Lymphoma (T-NHL) cases from Pakistan; correlating the immunohistochemical aspects of the disease with the molecular level by studying T-cell receptor (TCR) and Immunoglobulin Heavy (IgH) chain gene rearrangements and their association with Epstein-Barr virus (EBV) and Human T-cell Lymphotropic Virus Type-I (HTLV-I) infections.. As a post-doctoral fellow under the supervision of Dr. Juergen Vielkind, in the Department of Cancer Endocrinology at BC Cancer Research Centre, Vancouver, B.C., Canada, Dr. Assanie-Shivji identified the role of growth differentiation factor 15 (gdf15) in the development of the normal prostate during early stages of embryogenesis and in prostate cancer in a transgenic mouse model, 12T-7s.. After completing her post-doctoral ...
TY - JOUR. T1 - The aggressive peripheral T-cell lymphomas. T2 - 2012 update on diagnosis, risk stratification, and management. AU - Armitage, James O.. PY - 2012/5. Y1 - 2012/5. N2 - Background: T-cell lymphomas make up approximately 10-15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia. Diagnosis: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the WHO classification. The ability of hematopathologists to reproducibly diagnose aggressive PTCL is lower than for aggressive B-cell lymphomas, with a range of 72-97% for the aggressive PTCLs. Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography (PET) scans appear to be useful as they are in aggressive B-cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive ...
A 37-year-old female had noticed a mass on her right neck for about 2 weeks before her initial visit to our hospital. A magnetic resonance imaging (MRI) scan of the nasopharynx and neck showed mucosal thickening in the right nasopharynx, together with multiple deep cervical lymph node enlargements. She was diagnosed with extranodal NKTCL by excisions biopsy (nasopharyngeal mass biopsy and cervical mass biopsy) and was transferred to our hospital in October 2014. Immunohistochemical staining demonstrated that the tumor cells expressed surface CD2, cytoplasmic CD3Ɛ, TIA-1, and granzyme B, but not CD10, CD15, CD20, CD21, and PAX-5. Bone marrow examination showed no presence of neoplastic cells. She was confirmed as having Ann Arbor stage IIE extranodal NKTCL based on the radiological findings and laboratory tests. She underwent four cycles of interchangeable chemotherapy comprising VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone) and AspaMet (pegaspargase and methotrexate), followed by ...
Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less well understood. We used population-based cancer registry data to estimate the subtype-specific risks of second primary lymphoma among patients with first BCL (n=288,478) or TCL (n=23,747). We observed nearly five-fold increased bidirectional risk between BCL and TCL overall (TCL following BCL: standardized incidence ratio [SIR]=4.7, 95% confidence interval [CI]=4.2-5.2; BCL following TCL: SIR=4.7, 95%CI=4.1-5.2), but the risk varied substantially by lymphoma subtype. The highest SIRs were observed between Hodgkin lymphoma (HL) and peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) (PTCL-NOS following HL: SIR=27.5, 95%CI=18.4-39.4; HL following PTCL-NOS: SIR=31.6, 95%CI=17.3-53.0). Strikingly elevated risks also were notable for angioimmunoblastic T-cell lymphoma (AITL) ...
Mgr. Pavlína Čejková MOLECULAR-GENETIC STUDY OF POLYGENIC DISEASES WITH A SPECIAL FOCUS ON DIABETES MELLITUS Abstract Polygenic diseases with complex mode of inheritance constitute an increasing public health burden. The aim of this study was to contribute to our current knowledge in genetic background of several complex diseases, namely enteropathy-type T-cell lymphoma, type 1 and type 2 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis a psoriatic arthritis, in order to better understand the pathogenesis of the diseases with potential diagnostic, prognostic or therapeutic applications. In the ETL, previously detected gain in chromosome band 9q was further narrowed down by microsatellite analysis to 9q34, and gDNA-based quantitative PCR confirmed amplification of both, ABL1 and NOTCH1genes. HLA genotyping of T1D manifested in childhood, adult-onset T1D and LADA showed partially different genetic predispositions. This finding points out a possible role of environmental ...
TY - JOUR. T1 - Bone marrow manifestations of peripheral T-cell lymphoma. T2 - A study of 30 cases. AU - Hanson, C. A.. AU - Brunning, R. D.. AU - Gajl-Peczalska, K. J.. AU - Frizzera, G.. AU - McKenna, R. W.. PY - 1986/1/1. Y1 - 1986/1/1. N2 - Morphologic and clinical features of 30 patients with peripheral T-cell lymphoma (PTCL) were studied with particular attention to bone marrow and blood manifestations. Twenty-four (80%) patients had marrow involvement with lymphoma in trephine biopsies at initial diagnosis; two other patients subsequently developed marrow involvement. The bone marrow lesions were diffuse in 58% of the cases and focal, nonparatrabecular in 42%. A morphologic spectrum of lymphoma cells was seen with cases classified into small cell, mixed cell, and large cell/immunoblastic lymphoma. The bone marrow lesions were characterized by a heteromorphous population of lymphocytes, prominent vascularity with endothelial cell proliferation, reticulin fibrosis, and a polycellular ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
Federal drug regulators are warning that patients taking Enbrel, Humira and other similar drugs continue to report incidents of Hepatosplenic T-Cell
Nonhepatosplenic/noncutaneous |i|γδ|/i| peripheral T-cell lymphoma (NHNC|i|γδ|/i| PTCL) represents a miscellaneous group of unrelated T-cell lymphomas of which only isolated cases have been reported. We describe two cases of transformation from T-lymphoblastic leukemia/lymphoma to NHNC|i|γδ|/i| PTCL. Transformation into more aggressive disease is a rare event in T-cell lineage-derived hematologic malignancies compared to B-cell neoplasms. Nevertheless, both of our cases involved relapse as PTCL manifested with skin involvement and an overt shift from blastic morphology to large granular leukemia-like mature T cells. Among other notable molecular characteristics, expression of immature markers such as TdT was lost in both cases. Based on cytogenetics, phenotype, and morphology, both patients represent a novel phenomenon of clonal transformation from T-ALL to PTCL which has rarely been reported in the literature. Such transformation may carry important diagnostic and
You are visiting the general public version of the website.. If you are a health professional, register to discover a content especially tailored for you.. If you already have an account, log in! ...
How is transformation of cutaneous T-cell lymphoma abbreviated? t-CTCL stands for transformation of cutaneous T-cell lymphoma. t-CTCL is defined as transformation of cutaneous T-cell lymphoma rarely.
6 NCCN Guidelines for Patients ® Peripheral T-cell Lymphoma, Version 1.2016 Youve learned that you have or may have peripheral T-cell lymphoma. Its common to feel shocked and confused. Part 1 reviews some basics that may help you learn about this lymphoma and start to cope. These basics may also help you start planning for treatment. What is the lymphatic system? The lymphatic system is one of 13 systems of the human body. It transports fluids to the bloodstream and fights germs. As such, it supports your blood- flowing (cardiovascular) and disease-fighting (immune) systems. Cells are the building blocks of tissue in the body. The spaces between cells are filled with fluid. This fluid is called interstitial or tissue fluid. Most tissue fluid comes from parts of blood plasma that have passed out of blood vessels. Cells also release waste and other products into tissue fluid. When tissue fluid increases, it drains into vessels. Almost all of tissue fluid drains back into blood vessels. The rest ...
Lymphoma is cancer of the lymphatic_system. Lymphoma is broken down into two major types: hodgkins_disease and non-Hodgkins lymphoma. Various Types of Lymphoma (Not inclusive): adult T-cell lymphoma , adult T-cell leukemia/lymphoma see under leukemia. B-cell lymphoma any in a large group of non-Hodgkins lymphomas characterized by malignant transformation of the B lymphocytes. B-cell monocytoid lymphoma a low-grade lymphoma in which cells resemble those of hairy cell leukemia. Burkitts lymphoma a form of small noncleaved-cell lymphoma, usually occurring in Africa, manifested usually as a large osteolytic lesion in the jaw or as an abdominal mass; Epstein-Barr virus has been implicated as a causative agent. centrocytic lymphoma mantle cell l. convoluted T-cell lymphoma lymphoblastic lymphoma with markedly convoluted nuclei. cutaneous T-cell lymphoma a group of lymphomas exhibiting (1) clonal expansion of malignant T lymphocytes arrested at varying stages of differentiation of cells committed to ...
If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team ...
Incidence: More frequent in adults than children. Low incidence - approximately 10-15% of non-Hodgkins lymphoma. Account for about 12% of lymphoid tumours worldwide. Uncommon in North America. Peripheral T-Cell Lymphoma Unspecified is the most common group. Also see specific variants (subtypes), below. Grade: aggressive clinical course.. Staging: Staging refers to the how widespread the disease is. Imaging tests (CT MRI, PET, Gallium). See Staging for more detail.. Diagnosis requires analysis of tissue sample using a variety of tests to identify the cell type. T-cell markers will express CD4 or CD8, but not both. 1. Prognosis: Each lymphoma is unique and the prognosis can depend on many clinical factors, including the unique molecular and biological characteristics of the tumor, the patients age, general health and immune status, areas of involvement, how widespread the disease is at diagnosis (stage), and if so-called b-symptoms are present. ...
We use cookies to improve your experience and our website service. To read about our cookies policy, please read our privacy statement. By continuing to browse our site, you accept our use of cookies. ...
The purpose of this Phase 2 clinical trial is to find out if pembrolizumab can improve your disease and increase progression free survival; to determine the tolerability and safety of pembrolizumab; and if there are markers or special characteristics in the cancer tissue and blood that go along with response to treatment and survival.
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody - With BSA and Azide, Rabbit Polyclonal Antibody [Clone ] validated in WB, IHC, IF, FC (AH11384-20), Abgent
The purpose of this Phase 1/2, multi-center study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma (AITL), with an IDH2 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-221 to determine maximum tolerated dose (MTD) and/or the recommended Phase 2 dose. The second portion of the study is a planned dose expansion phase where three cohorts of patients will receive AG-221 to further evaluate the safety, tolerability, and clinical activity. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs ...
Free, official coding info for 2021 ICD-10-CM C86.1 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
TY - JOUR. T1 - FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. AU - Kuo, Phillip H. AU - McClennan, Bruce L.. AU - Carlson, Kacie. AU - Wilson, Lynn D.. AU - Edelson, Richard L.. AU - Heald, Peter W.. AU - Girardi, Michael. PY - 2008/3. Y1 - 2008/3. N2 - This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) positron-emission tomography/ computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick ...
In a recent issue of Blood, Mathas et al suggested elevated BCL3 expression to be functionally important in classical Hodgkin lymphoma (cHL) and peripheral T-cell lymphoma (PTCL). The authors reported strong BCL3 protein expression in the vast majority of cHLs and a subset of PTCLs.1 These results corroborated similar immunohistochemical findings by Canoz et al. Mathas et al reported chromosomal gains of the BCL3 locus in chromosome band 19q13 as a potential cause of BCL3 upregulation in 3 of 6 cHL cell lines and 8 of 37 PTCLs. Here, we provide evidence that not only chromosomal gains but also translocations affecting the BCL3 locus are recurrent in cHL and PTCL. [beginning of text ...
The second line of evidence showing a role for epigenetic therapy in T-cell lymphoma is the activity of HDAC inhibitors. As of the recent approval of belinostat for PTCL, there are three approved agents of this class. Vorinostat was approved for CTCL, then romidepsin for CTCL and PTCL, and recently belinostat (82-87). These agents inhibit HDACs (erasers in Fig. 1), leading to an increase in the expression of genes that cause cell-cycle arrest or apoptosis. Vorinostat and belinostat are hydroxamic acid derivatives that inhibit both class I and II HDACs, whereas romidepsin is a cyclic peptide that inhibits primarily the class I HDACs. The class II HDACs deacetylate a number of cytoplasmic proteins, including Hsp90 and tubulin, which may play a role in HDAC inhibitor activity in some models. The activity of all three agents in T-cell lymphoma suggests that inhibition of the class I HDACs may be the decisive factor in this disease.. It has become increasingly clear that HDAC inhibitors have a more ...
Natural killer/T-cell lymphoma (NKTCL) is an aggressive subtype of non-Hodgkin lymphoma that has poor prognosis and no available targeted therapy. Mutations in TP53, NRAS, and genes in the JAK-STAT pathway have been identified in NKTCL, but the role of these and other as-yet-unidentified driver mutations in the molecular pathogenesis of NKTCL has not been fully elucidated. To identify additional genetic alterations that may drive NKTCL tumorigenesis, Jiang and colleagues performed whole-exome sequencing of matched tumor and normal samples from 25 patients with NKTCL and identified mutations in 795 genes that were predicted to alter protein function. Based on the presence of recurrent mutations predicted to modulate functions and relevance to oncogenesis, 26 of the 795 genes were selected for validation in 80 patients with NKTCL. The RNA helicase gene DEAD box helicase 3, X-linked (DDX3X), mutated in 21 (20%) of 105 patients, was found to be the most frequently mutated gene. In addition, ...
TY - JOUR. T1 - Peripheral T-cell lymphomas. T2 - very little good, mainly the bad and the ugly. AU - Bennani, Nabila. AU - Ansell, Stephen Maxted. PY - 2017/6/2. Y1 - 2017/6/2. UR - http://www.scopus.com/inward/record.url?scp=85020212421&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85020212421&partnerID=8YFLogxK. U2 - 10.1080/10428194.2017.1326035. DO - 10.1080/10428194.2017.1326035. M3 - Article. C2 - 28573916. AN - SCOPUS:85020212421. SP - 1. EP - 2. JO - Leukemia and Lymphoma. JF - Leukemia and Lymphoma. SN - 1042-8194. ER - ...
Expression profiling using DNA microarrays has been very helpful to improve our knowledge of the pathobiology of many tumour types, including lymphomas. Peripheral T-cell lymphomas (PTCL) constitute an heterogeneous group of tumours with different morphologic, immunophenotypic, and clinical characteristics. Their complexity and their low frequency in the western countries have made difficult the identification of molecular events responsible of the development of these tumours. The first studies on expression profiling of PTCL have also revealed heterogeneity at this level, mainly regarding the PTCL NOS subgroup. Different molecular subgroups within PTCL unspecified have been identified associated to different expression profiles. However, the clinical significance of this molecular sub-classification remains to be probed in studies involving larger number of samples. In addition, the expression level of NF-kB pathway genes allowed to differentiate two PTCL subgroups, and this difference could ...
A Discussion About Treatment Options for PTCL Patients With Dr. David Christopher FisherAssistant Professor of Medicine at Harvard Medical School, Boston, Massachusetts Can you describe peripheral T-cell lymphoma?
Press Release issued Aug 5, 2014: Reportstack, provider of premium market research reports announces the addition of Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2014 market report to its offering
TY - JOUR. T1 - Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. AU - Schatz, J. H.. AU - Horwitz, S. M.. AU - Teruya-Feldstein, J.. AU - Lunning, M. A.. AU - Viale, A.. AU - Huberman, K.. AU - Socci, N. D.. AU - Lailler, N.. AU - Heguy, A.. AU - Dolgalev, I.. AU - Migliacci, J. C.. AU - Pirun, M.. AU - Palomba, M. L.. AU - Weinstock, D. M.. AU - Wendel, H. G.. PY - 2015/1/10. Y1 - 2015/1/10. UR - http://www.scopus.com/inward/record.url?scp=84920670383&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84920670383&partnerID=8YFLogxK. U2 - 10.1038/leu.2014.261. DO - 10.1038/leu.2014.261. M3 - Letter. C2 - 25257991. AN - SCOPUS:84920670383. VL - 29. SP - 237. EP - 241. JO - Leukemia. JF - Leukemia. SN - 0887-6924. IS - 1. ER - ...
78 NCCN Guidelines for Patients ® Peripheral T-cell Lymphoma, Version 1.2016 State Fundraising Notices State Fundraising Notices FLORIDA: A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION OF NCCN FOUNDATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE WITHIN THE STATE 1-800-HELP-FLA. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. FLORIDA REGISTRATION #CH33263. GEORGIA: The following information will be sent upon request: (A) A full and fair description of the programs and activities of NCCN Foundation; and (B) A financial statement or summary which shall be consistent with the financial statement required to be filed with the Secretary of State pursuant to Code Section 43-17-5. KANSAS: The annual financial report for NCCN Foundation, 275 Commerce Drive, Suite 300, Fort Washington, PA 19034, 215-690-0300, State Registration # 445-497-1, is filed with the Secretary of State. MARYLAND: A copy of the NCCN Foundation ...
Stephen M. Ansell, MD, PhD, provides a general overview of peripheral T-cell lymphoma and a retrospective outlook on the advancement of treatment.
Simian T-cell lymphoma/leukemia virus-1 (STLV-1) infection of non-human primates can serve as a model for human T-cell lymphoma/leukemia virus infection. Two tantalus and 2 patas monkeys were transfused with intraspecies whole blood infected with STLV-1. Infection was determined by ELISA, western blot and DNA PCR analyses. The entire genome of the STLV-1 Tan 90 strain and some of the STVL-1 Pat74 strain were amplified using over-lapping primer-pairs and subsequently sequenced. Followup studies conducted over 2 years indicated that all 4 monkeys remained healthy despite being infected with STLV-1, as determined by PCR, cloning and sequencing analyses. ELISA and Western blot analyses indicated that both patas monkeys seroconverted within 2 months of transfusion, while one tantalus monkey required one year to seroconvert and the other never fully seroconverted. The tantalus monkey which never fully seroconverted, failed to react to HTLV-1 p24 Gag antigen. Sequence analyses indicated that, while unique, the
Cutaneous T-cell lymphoma is a term that was created in 1979 at an international workshop sponsored by the National Cancer Institute (NCI) to describe a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. (For lymphomas in general, the skin is actually the second most common extranodal...
Cutaneous T-cell lymphoma is a term that was created in 1979 at an international workshop sponsored by the National Cancer Institute (NCI) to describe a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. (For lymphomas in general, the skin is actually the second most common extranodal...
I had a knot come up on the back of my head on the left side at the base of my skull a couple weeks ago. Went to dr. next day, he removed it two days later (thought it was a sebacious cyst). A day after that called me and asked me to go to the oncologist as the pathology report was suspicious. Went to the oncologist that afternoon and oncologist told me that what the other dr removed was Cutaneous T-Cell Lymphoma (as per the pathologist). Well, the oncologist scheduled me for a PET scan the next week and said that the PET scan would pick up the smallest spec of any cancer in my body and that if anything showed up, it would be considered cancer as they would inject a radioactive glucose in and IV and have it go through my body prior to the scan. If any cancer, the cancer would suck up the radioactive glucose and be hi-lighted under the scan indicating a malignancy. Went for the follow up with the oncologist and he said the PET scan showed two lymph nodes enlarged and malignancies in them. He ...
Non-Hodgkin's lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone. CHOP. Germ cell tumor. Bleomycin, etoposide, ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ... M - mitosis; where the cell divides to produce two daughter cells that continue the cell cycle. ... cells that produce white and red blood cells) are destroyed, meaning allogenic or autologous bone marrow cell transplants are ...
Mantle cell lymphoma Kite Pharma selpercatinib[15] RET fusion-positive non-small cell lung cancer Eli Lilly ... MET exon 14 skipping mutated non-small cell lung cancer Novartis KTE-X19[15] ...
... expansion may be seen in benign, such as Castleman disease, and malignancy, i.e., Mantle cell lymphoma. Tcl-1 is ...
cutaneous T-cell lymphoma (CTCL) Diphtheria toxin engineered protein combining Interleukin-2 and Diphtheria toxin Interleukin-2 ... mammalian cell lines (see cell culture) and plant cell cultures (see plant tissue culture) and moss plants in bioreactors of ... somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can ... banks for reproductive cells are much more widespread and available due to the ease of which spermatozoa and egg cells are able ...
"Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin". Leuk. Lymphoma. 43 (2): 393-9. ... Cell. Biol. 24 (14): 6430-44. doi:10.1128/MCB.24.14.6430-6444.2004. PMC 434232. PMID 15226443. Okada T, Noji S, Goto Y, Iwata T ... Cell Genet. 88 (3-4): 200-1. doi:10.1159/000015546. PMID 10828585. S2CID 84779733. Kondo E, Horii A, Fukushige S (2001). "The ...
"Notch signaling induces cell cycle arrest in small cell lung cancer cells". Cancer Res. 61 (7): 3200-5. PMID 11306509. Shimizu ... Lymphoma. 46 (2): 157-65. doi:10.1080/10428190400010742. PMID 15621797. S2CID 36863790. Stifani S, Blaumueller CM, Redhead NJ, ... Cell. Biol. 20 (18): 6913-22. doi:10.1128/MCB.20.18.6913-6922.2000. PMC 88767. PMID 10958687. Wu L, Aster JC, Blacklow SC, Lake ... Cell. Biol. 18 (4): 2324-33. doi:10.1128/mcb.18.4.2324. PMC 121486. PMID 9528802. Berezovska O, Xia MQ, Hyman BT (1998). "Notch ...
Cell. Biol. 19 (3): 1810-20. doi:10.1128/MCB.19.3.1810. PMC 83974. PMID 10022868. Li W, Nagineni CN, Hooks JJ, Chepelinsky AB, ... Lymphoma. 35 (5-6): 507-11. doi:10.1080/10428199909169615. PMID 10609788. Staal A, Enserink JM, Stein JL, Stein GS, van Wijnen ... Cell. Biol. 19 (3): 1810-20. doi:10.1128/MCB.19.3.1810. PMC 83974. PMID 10022868. Harada H, Taniguchi T, Tanaka N (1999). "The ... Cell. Biol. 14 (2): 1500-9. doi:10.1128/MCB.14.2.1500. PMC 358505. PMID 7507207. Adams MD, Kerlavage AR, Fleischmann RD, ...
Avraham S, Avraham H (1997). "Characterization of the novel focal adhesion kinase RAFTK in hematopoietic cells". Leuk. Lymphoma ... cell adhesion, and osteoclast motility". J. Cell Biol. 152 (1): 181-95. doi:10.1083/jcb.152.1.181. PMC 2193648. PMID 11149930. ... Cell. Biol. 19 (3): 2338-50. doi:10.1128/MCB.19.3.2338. PMC 84026. PMID 10022920. Seabold GK, Burette A, Lim IA, Weinberg RJ, ... Cell. Biol. 19 (3): 2278-88. doi:10.1128/mcb.19.3.2278. PMC 84020. PMID 10022914. Chauhan D, Pandey P, Hideshima T, Treon S, ...
Oldenborg PA (2004). "Role of CD47 in erythroid cells and in autoimmunity". Leuk. Lymphoma. 45 (7): 1319-27. doi:10.1080/ ... SIRPα recognizes CD47, an anti-phagocytic signal that distinguishes live cells from dying cells. CD47 has a single Ig-like ... This interaction negatively controls effector function of innate immune cells such as host cell phagocytosis. SIRPα diffuses ... Oldenborg PA (2013). "CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and ...
Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is ... Lymphoma. 44 (1): 1-7. doi:10.1080/1042819021000040233. PMID 12691136. S2CID 28533250. Kottaridis PD, Gale RE, Linch DC (2003 ... CD135 is important for lymphocyte (B cell and T cell) development. Two cytokines that down modulate FLT3 activity (& block FLT3 ... used to identify the cell type, stage of differentiation and activity of a cell. In mice, CD135 is expressed on several ...
... homology to other integrins and a possible cell-cell adhesion function". EMBO J. 8 (5): 1361-8. doi:10.1002/j.1460-2075.1989. ... Lymphoma. 24 (5-6): 423-35. doi:10.3109/10428199709055581. PMID 9086434. Porter JC, Hogg N (1999). "Integrins take partners: ... "Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis". J. Cell Sci. 113 (Pt 13): 2385-97. PMID 10852818 ... Comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY". J. Biol. Chem. 267 (12): 8366-70. PMID ...
Most immune cells (or leukocytes) secrete TGF-β1. Some T cells (e.g. regulatory T cells) release TGF-β1 to inhibit the actions ... Lymphoma. 43 (1): 51-7. doi:10.1080/10428190210195. PMID 11908736. S2CID 28490341. Schnaper HW, Hayashida T, Hubchak SC, ... It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell ... However, as with other cell types, TGF-β1 can also have the opposite effect on cells of myeloid origin. For example, TGF-β1 ...
"Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leuk. Lymphoma. 43 (2): 233-41. doi:10.1080 ... airway smooth muscle cells and endothelial cells. Endothelial cells store IL-8 in their storage vesicles, the Weibel-Palade ... there are a relatively wide range of cells (endothelial cells, macrophages, mast cells, and keratinocytes) that respond to this ... and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been ...
Hori Y, Gu X, Xie X, Kim SK (2005). "Differentiation of insulin-producing cells from human neural progenitor cells". PLOS Med. ... Lymphoma. 31 (5-6): 599-608. doi:10.3109/10428199809057620. PMID 9922051. Prévôt D, Voeltzel T, Birot AM, Morel AP, Rostan MC, ... Cell Genet. 73 (1-2): 114-5. doi:10.1159/000134320. PMID 8646877. Ohnishi K, Tobita T, Sinjo K, Takeshita A, Ohno R (1998). " ... Cell. Biol. 21 (21): 7509-22. doi:10.1128/MCB.21.21.7509-7522.2001. PMC 99922. PMID 11585930. Kosaki K, Kosaki R, Suzuki T, ...
Baron ED, Stevens SR (2003). "Phototherapy for cutaneous T-cell lymphoma". Nih.gov. 16 (4): 303-10. PMID 14686973.. ... cutaneous T-cell lymphoma[15] and lichen planus. Narrowband UVB lamps, 311-313 nanometer is the most common treatment.[16] ... When they sense UV light the cells manufacture the pigment in order to protect the body from the harming UV light. Treatment is ... Photo therapy is an effective treatment because the skin cells manufacture the pigment when they sense UV light. ...
... translocation in a patient with diffuse large B-cell lymphoma". Blood. 95 (8): 2719-21. doi:10.1182/blood.V95.8.2719. PMID ... IKZF1 is upregulated in granulocytes, B cells, CD4 and CD8 T cells, and NK cells, and downregulated in erythroblasts, ... In Ikaros knockout mice, T cells but not B cells are generated late in mouse development due to late compensatory expression of ... The dysfunction affects expression in B cells that can lead to deregulation of the BCR signaling during B cell development and ...
"Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leukemia & Lymphoma. 43 (2): 233-41. doi: ... "Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand". Cell. 109 ( ... For example, its increased expression was seen in a metastatic mammary cancer cell line. Gelatinase B plays a central role in ... Lastly, there is significant evidence that Gelatinase B is required for the recruitment of endothelial stem cells, a critical ...
Bruchova-Votavova H, Yoon D, Prchal JT (2010). "miR-451 enhances erythroid differentiation in K562 cells". Leuk Lymphoma. 51 (4 ... "MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells". Mol Cell. 37 (5): 620- ... Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S (2010). "microRNA-451: A conditional switch controlling glioma cell ... Cell Biology. 42 (8): 1282-1290. doi:10.1016/j.biocel.2010.01.014. PMID 20083225. Courts, C; Madea, B (Aug 9, 2011). "Specific ...
T-cell leukemia homeobox protein 1 is a protein that in humans is encoded by the TLX1 gene, which was initially named HOX11. ... Lymphoma. 39 (3-4): 241-56. doi:10.3109/10428190009065824. PMID 11342305. S2CID 27407074. Lu M, Zhang N, Ho AD (Jul 1992). " ... Lu M, Gong ZY, Shen WF, Ho AD (Oct 1991). "The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia ... "Entrez Gene: TLX1 T-cell leukemia homeobox 1". Kennedy MA, Gonzalez-Sarmiento R, Kees UR, Lampert F, Dear N, Boehm T, Rabbitts ...
DNA sequencing of miR-17-92 cluster at chromosome 13q31-q32 in mantel cell lymphoma cell lines]". Zhongguo Shi Yan Xue Ye Xue ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... "Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma". Mod ...
Johnston, JB (June 2011). "Mechanism of action of pentostatin and cladribine in hairy cell leukemia". Leukemia & Lymphoma. 52 ... cladribine targets B cells more than T cells. Both HCL and B-cell chronic lymphocytic leukaemia are types of B cell blood ... which causes it to accumulate in cells and interfere with the cell's ability to process DNA. Cladribine is taken up by cells ... the cells with the highest ratios are B cells, especially germinal centre and naive B cells. This again helps to explain which ...
Cell. 128 (2): 257-67. doi:10.1016/j.cell.2006.11.046. PMID 17254965. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ ... "Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma". Leuk. Lymphoma. 45 (5 ... "Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma". Leukemia & Lymphoma. ... PIM2 is expressed with high levels in the brain and lymphoid cells. PIM1-3 compound knockout mice that survived the perinatal ...
... is most frequently found on plasma B cells, followed by natural killer cells, followed by B cells and T cells, and then ... Sidiqi MH, Gertz MA (February 2019). "Daratumumab for the treatment of AL amyloidosis". Leukemia & Lymphoma. 60 (2): 295-301. ... CD31 on endothelial cells binds to the CD38 receptor on natural killer cells for those cells to attach to the endothelium. CD38 ... In 1992 it was additionally described as a surface marker on B cells, monocytes, and natural killer cells (NK cells). About the ...
Allen TD, Zhu YX, Hawley TS, Hawley RG (Oct 2000). "TALE homeoproteins as HOX11-interacting partners in T-cell leukemia". ... Leukemia & Lymphoma. 39 (3-4): 241-56. doi:10.3109/10428190009065824. PMID 11342305. S2CID 27407074. Bonaldo MF, Lennon G, ... "HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells". Molecular and Cellular Biology. 19 (4): 3051-61. doi: ... "HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells". Molecular and Cellular Biology. 19 (4): 3051-61. doi: ...
September 2003). "Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation". Leukemia & Lymphoma. 44 (9): 1477-81 ... B cell isoform of 220 kDa). B220 expression is not restricted to B cells and can also be expressed on activated T cells, on a ... It is the longest protein and migrates at 200 kDa when isolated from T cells. B cells also express CD45R with heavier ... except erythrocytes and plasma cells). CD45 has been shown to be an essential regulator of T- and B-cell antigen receptor ...
CX-5461 activates p53 via nuclear stress and induces apoptosis of leukemia and lymphoma cells while leaving normal cells ... The promise of these drugs is that they leave healthy cell DNA unharmed and specifically target the fact that cancer cells rely ... It has been said that ribosome biogenesis is the "Achilles heel in cancer cells." Nakhoul H, Ke J, Zhou X, et al. (2014). " ... Zhou X, Liao WJ, Liao JM, Liao P, Lu H (2015). "Ribosomal proteins: functions beyond the ribosome". J Mol Cell Biol. 7 (2): 92- ...
"Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human". Cancer Research. 66 (2): 812-9. doi:10.1158/ ... Olbrot M, Rud J, Moss LG, Sharma A (May 2002). "Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 ... DePianto DJ, Blankenship TN, Hess JF, FitzGerald PG (Jun 2003). "Analysis of non-crystallin lens fiber cell gene expression in ... Cousins DJ, Lee TH, Staynov DZ (Sep 2002). "Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence ...
Sun L, Kerawalla H, Wu X, Lehnert MS, Uckun FM (Apr 2002). "Expression of a unique helios isoform in human leukemia cells". ... Leukemia & Lymphoma. 43 (4): 841-9. doi:10.1080/10428190290016980. PMID 12153174. S2CID 8170745. Durand C, Kerfourn F, ... Immunology and Cell Biology. 81 (3): 171-5. doi:10.1046/j.1440-1711.2003.01159.x. PMID 12752680. S2CID 43733744. Sridharan R, ... a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin". Genes & ...
It is known that EpoR can activate mitogenic signaling pathways and can lead to cell proliferation in erythroleukemic cell ... Lymphoma. 43 (2): 261-4. doi:10.1080/10428190290006026. PMID 11999556. S2CID 34605746. Kralovics R, Skoda RC (Jan 2005). " ... Primary role of EpoR is to promote proliferation of erythroid progenitor cells and rescue erythroid progenitors from cell death ... Cell. 126 (2): 415-26. doi:10.1016/j.cell.2006.06.037. PMID 16873070. Wu H, Liu X, Jaenisch R, Lodish HF (Oct 1995). " ...
Lymphoma. 18 (1-2): 51-9. doi:10.3109/10428199509064922. PMID 8580829. Agematsu K (April 2000). "Memory B cells and CD27". ... CD27 is expressed on both naïve and activated effector T cells as well as NK cells and activated B cells. It is a type I ... This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key ... In murine γδ T cells its expression has been correlated with the secretion of IFNγ. Varlilumab is an IgG1 antibody that binds ...
The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容 (PDF)存档于2008-07-06).. 已忽略未知参数. ,url- ... T Cells to protect tumour cells. Nature Communications. March 2018, 9 (1): 948. PMC 5838096. PMID 29507342. doi:10.1038/s41467- ... 细胞毒性T细胞(CTLs, killer T cells)负责杀伤被病毒感染的细胞和癌细胞,在对器官移植的免疫排斥中也有参与。其特点在于细胞表面的CD8蛋白质。
"Blood Cells Mol. Dis. 39 (3): 336-9. doi:10.1016/j.bcmd.2007.06.009. PMC 2387274. PMID 17698380.. ... Lymphoma. 50 (6): 1043-6. doi:10.1080/10428190902913591. PMID 19391034.. *. Meester-Smoor MA, Janssen MJ, Grosveld GC, et al. ( ... Cell. Proteomics. 7 (3): 499-508. doi:10.1074/mcp.M700325-MCP200. PMID 18029348.. ... 2009). "Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic ...
B. C. Giovanella u. a.: Development of invasive tumors in the nude mouse after injection of cultured human melanoma cells. In: ... C. O. Povlsen, J. Rygaard: Effects of Cyclophosphamide (Endoxan R) on a Burkitt´s Lymphoma serially grown in nude mice. In: ... L. Miers u. a.: Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth ... T. Devos u. a.: Occurrence of autoimmunity after xenothymus transplantation in T-cell-deficient mice depends on the thymus ...
... particularly in Hodgkin's lymphoma, non-Hodgkin lymphoma, and lung cancer.[citation needed] ... This tracer is a glucose analog that is taken up by glucose-using cells and phosphorylated by hexokinase (whose mitochondrial ... This means that FDG is trapped in any cell that takes it up until it decays, since phosphorylated sugars, due to their ionic ... PET in the management of patients with non-small-cell lung cancer (NSCLC). Journal of Experimental & Clinical Cancer Research ...
... is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.[44] In 2010 it was ... cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In ... The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in ... Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ...
... treated with stem cell transplants include sickle-cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ... Sources and storage of cells[edit]. To limit the risks of transplanted stem cell rejection or of severe graft-versus-host ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ...
It has received regulatory approval for use as a treatment for non-small cell lung cancer,[6][4][7][8] although there is ... Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Obinutuzumab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), ... Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ...
Lymphoma 43 (7): 1367-73. PMID 12389615. doi:10.1080/10428190290033297. *Zhou T, Zhang J, Carter R, Kimberly R (2003). "BLyS ... Brink R (2007). "Regulation of B cell self-tolerance by BAFF.". Semin. Immunol. 18 (5): 276-83. PMID 16916609. doi:10.1016/j. ... Mackay F, Leung H (2007). "The role of the BAFF/APRIL system on T cell function.". Semin. Immunol. 18 (5): 284-9. PMID 16931039 ... Tangye SG, Bryant VL, Cuss AK, Good KL (2007). "BAFF, APRIL and human B cell disorders.". Semin. Immunol. 18 (5): 305-17. PMID ...
Primary central nervous system lymphoma, Sphenoid wing meningioma, Subependymal giant cell astrocytoma, Subependymoma, ... Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells ... Necrotic cells send the wrong chemical signals which prevent phagocytes from disposing of the dead cells, leading to a buildup ... Glial cells such as Schwann cells in the periphery or, within the cord itself, oligodendrocytes, wrap themselves around the ...
... or tumors such as lymphoma or squamous cell carcinoma. A tonsillolith (also known as a "tonsil stone") is material that ... These M cells then alert the underlying B cells and T cells in the tonsil that a pathogen is present and an immune response is ... The tonsils have on their surface specialized antigen capture cells called M cells that allow for the uptake of antigens ... "Tonsils Make T-Cells, Too, Ohio State Study Shows". Ohio State University. Ohio State University, Comprehensive Cancer Center. ...
Cells, circulating tumor cells (CTCs), or formalin-fixed paraffin-embedded (FFPE) or frozen tissue sections are fixed, then ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ... FISH can also be used to detect diseased cells more easily than standard Cytogenetic methods, which require dividing cells and ... "Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2". PLOS ONE. 7 ...
"Molecular Cell. 68 (1): 130-143.e5. doi:10.1016/j.molcel.2017.08.016. PMC 5632562. PMID 28918903.. ... "Letter: Chemotherapy of advanced histocytic lymphomas". Lancet. 1 (7916): 6300-3. doi:10.1016/s0140-6736(75)92521-0. PMC 49488 ... In specific cell types or on specific promoters TBP can be replaced by one of several TBP-related factors (TRF1 in Drosophila, ... Compounds that trap the protein-DNA intermediate could result in it being toxic to the cell once they encounter a DNA ...
"Cell. 171 (3): 522-539.e20. doi:10.1016/j.cell.2017.08.032. ISSN 0092-8674.. ... Principal cancer types under study: breast, prostate, blood (leukemia, lymphoma); melanoma; liver; ovarian and cervical; lung; ... Plant genome sequencing; epigenetics and stem cell fate; stem cell signaling; plant-environment interactions; using genetic ... Cell biology and genomics. RNA interference (RNAi) and small-RNA biology; DNA replication; RNA splicing; signal transduction; ...
Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... For example, JCV has been found to infect the granule cell layer of the cerebellum, while sparing purkinje fibers, ultimately ... Immunohistochemical detection of JC virus protein (stained brown) in a brain biopsy (glial cells demonstrating progressive ... and can also infect the tubular epithelial cells in the kidneys,[7] where it continues to reproduce, shedding virus particles ...
Lymphoma. M. *Macmillan Cancer Support. *Male breast cancer. *Melanoma. *Merkel-cell carcinoma ...
B-cell lymphoma - B cells - B lymphocytes (B cells) - bactericidal - bacteriostatic - bacterium - baculovirus - baseline - ... T suppressor cells - T4 cell - T4 cells (T-helper cells) - T8 cells - Tanner staging - TAT - TB - template - TeachAIDS - ... cells - CDC National Prevention Information Network (CDC-NPIN) - cell lines - cell-mediated immunity (CMI) - cellular immunity ... NK cell - NLM - NNRTI - non-Hodgkin's lymphoma (NHL) - non-nucleoside reverse transcriptase inhibitors (NNRTI) - non-steroidal ...
Of the various tumors of the blood and lymph, cancers of WBCs can be broadly classified as leukemias and lymphomas, although ... T cells: *CD4+ helper T cells: T cells displaying co-receptor CD4 are known as CD4+ T cells. These cells have T-cell receptors ... B cells: releases antibodies and assists activation of T cells. *T cells: *CD4+ Th (T helper) cells: activate and regulate T ... Natural killer cells: virus-infected and tumor cells.. Deeply staining, eccentric. NK-cells and cytotoxic (CD8+) T-cells. Years ...
cell volume homeostasis. • nucleocytoplasmic transport. • protein localization. • positive regulation of cell proliferation. • ... 2007). «Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.». Haematologica. 92 (4 ... J Cell Biol. 183 (4): 589-95. PMC 2582899. . PMID 19015314. doi:10.1083/jcb.200807185. !CS1 manut: Uso explícito de et al. ( ... Cell. Biol. 11 (5): 2567-75. PMC 360026. . PMID 2017166. !CS1 manut: Uso explícito de et al. (link) !CS1 manut: Nomes múltiplos ...
... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... such as lymphoma). The nature of the infections, as well as the additional features, may provide clues as to the exact nature ... natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells). Tests for T cell ... Normal numbers of B cells with decreased IgG and IgA and increased IgM: Hyper-IgM syndromes Normal numbers of B cells with ...
It is widely used in PUVA (psoralen + UVA) treatment for psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma; these ... Escherichia coli cells deficient in HRR are highly sensitive to PUVA compared to wild-type cells.[22] HRR appears to be ... "Cell. 165 (5): 1267-1279. doi:10.1016/j.cell.2016.04.028. PMC 5029792. PMID 27180905.. ... In E. coli, even though one or two unrepaired crosslinks are sufficient to inactivate a cell, a wild-type cell can repair and ...
"Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to ... cell-cell signaling. • positive regulation of brain-derived neurotrophic factor receptor signaling pathway. • collateral ... regulation of protein localization to cell surface. • regulation of receptor activity. • activation of phospholipase C activity ... BDNF binds at least two receptors on the surface of cells that are capable of responding to this growth factor, TrkB ( ...
Mendenhall WM, Olivier KR, Lynch JW, Mendenhall NP (April 2006). "Lethal midline granuloma-nasal natural killer/T-cell lymphoma ... a type of white blood cell) are associated with GPA.[11] Involvement of the ears, nose, and throat is more common in ... and many giant cells.[16] Bacterial colonization with Staphylococcus aureus has been hypothesized as an initiating factor of ... and decreases the incidence of abnormally low white blood cell counts by one-third.[8] However, pulsed intravenous ...
"Apoptotic cells in allogeneic hematopoietic stem cell transplantations: "turning trash into gold"". Leukemia & Lymphoma. 53 (11 ... be rejected by the body and biological functions such as cell adhesion and growth will be enhanced through cell-cell and cell- ... "CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion". Glia. 52 (3): 252-8. doi: ... Olfactory ensheathing cells (OECs), also known as olfactory ensheathing glia or olfactory ensheathing glial cells, are a type ...
2003). "Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leuk. Lymphoma 43 (2): 233-41. PMID ... Yuan A, Chen JJ, Yao PL, Yang PC (2006). "The role of interleukin-8 in cancer cells and microenvironment interaction". Front. ... human venular endothelial cells store interleukin 8 in Weibel-Palade bodies". J. Exp. Med. 188 (9): 1757-62. PMC 2212526. PMID ... "Rapid secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular endothelial cells". J. Exp. Med. 188 (9 ...
Mantle cell lymphoma/Multiple myeloma t(11 CCND1:14 IGH). *Anaplastic large-cell lymphoma t(2 ALK;5 NPM1) ... The 46/47 annotation indicates that the XY cells have the normal number of 46 total chromosomes, and the XXY cells have a total ... After further rounds of replication, this cell would result in a patch, or "clone" of cells mutant for the allele being studied ... they can be used to determine the tissue or cell type in which a given gene is required and to determine whether a gene is cell ...
Lymphoma 43 (3): 635-9. PMID 12002771. doi:10.1080/10428190290012182. *Marie PJ, Debiais F, Haÿ E (2003). "Regulation of human ... anat (c/f/k/f, u, t/p, l)/phys/devp/cell ... protein receptor complexes on the surface of live cells: a new ... Kawamura C, Kizaki M, Ikeda Y (2003). "Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells.". Leuk. ... Cell 11 (3): 1023-35. PMC 14828. PMID 10712517. doi:10.1091/mbc.11.3.1023. ...
Iijima S, Teraoka H, Date T, Tsukada K (1992). "DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation ... Cell Genet. 57 (2-3): 109-11. PMID 1914517. doi:10.1159/000133124. CS1 održavanje: Eksplicitna upotreba et al. (link) ... Dang CV, O'donnell KA, Juopperi T (2005). "The great MYC escape in tumorigenesis". Cancer Cell 8 (3): 177-8. PMID 16169462. doi ... 2002). "EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma". Curr. Top. Microbiol. Immunol. 258: 153-60. ...
... looks for the presence of red blood cells, white blood cells, or bacteria. Urine culture is deemed positive if it shows a ... Multiple white cells seen in the urine of a person with a urinary tract infection using a microscopy. ... Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white blood cells in urinary ... In those who have bacteria or white blood cells in their urine but have no symptoms, antibiotics are generally not needed,[14] ...
Schenkein D (June 2002). "Proteasome inhibitors in the treatment of B-cell malignancies". Clinical Lymphoma. 3 (1): 49-55. doi: ... "Cell. 137 (1): 133-45. doi:10.1016/j.cell.2009.01.041. PMC 2668214. PMID 19345192.. ... Cell cycle controlEdit. Cell cycle progression is controlled by ordered action of cyclin-dependent kinases (CDKs), activated by ... Apoptosis is mediated through disrupting the regulated degradation of pro-growth cell cycle proteins.[88] However, some cell ...
Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ... "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ...
Anaplastic large-cell lymphoma is an example of a large-cell lymphoma that involves T cells. Of the large-cell T-cell lymphomas ... B cell[edit]. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase " ... which are often diffuse large-B-cell lymphomas. Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be ... Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. ...
Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma involving aberrant T cells or ... The cells are also typically positive for a subset of markers of T-cell lineage. However, as with other T-cell lymphomas, they ... It has been suggested that ALK-negative anaplastic large-cell lymphomas derive from other T-cell lymphomas that are morphologic ... Other mimics include CD30 positive B-cell lymphomas with anaplastic cells (including Hodgkin lymphomas). These are identified ...
... is a form of non-Hodgkins lymphoma. The prognosis of MCL is poor because patients are typically diagnosed in stage IV. Read ... Mantle cell lymphoma (MCL) is a relatively rare type of cancer of the lymphoid cells; it is termed mantle cell lymphoma because ... home/cancer health center/cancer a-z list/mantle cell lymphoma mcl center /mantle cell lymphoma (mcl) article ... Mantle cell lymphoma (MCL) is a relatively rare cancer of the lymphoid cells that arises from the outer rim or mantle lymphoid ...
it gets its name because the cancer cells spread out (diffuse) all over the lymph node. ... diffuse b-cell lymphoma is a type of non-hodgkins lymphoma. ... "Types of B-Cell Lymphoma," "Types of T-Cell Lymphoma," "What is ... "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell ... "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell ...
If you have mantle cell lymphoma, youll likely see a variety of specialists like hematologists, oncologists, and social ... American Society of Hematology Clinical News: "Understanding Mantle Cell Lymphoma.". Joshua Brody, MD, director, lymphoma ... A hematologist may also be the specialist who does stem cell therapy for mantle cell lymphoma. ... After you get a diagnosis of mantle cell lymphoma, youll likely need a few imaging tests, such as a chest X-ray, body CT scan ...
Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy A one-year follow-up study led by The University of ... Tumor cell-based vaccine may prevent relapse of mantle cell lymphoma A phase I/II clinical trial by researchers at Stanford ... First CAR T-cell therapy for mantle cell lymphoma receives FDA approval Todays Food and Drug Administration approval of the ... Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19 A one-year follow-up study led by ...
Most (ie, 80-90%) NHLs are of B-cell origin. ... Non-Hodgkin lymphoma (NHL) is a collective term for a ... encoded search term (B-Cell Lymphoma) and B-Cell Lymphoma What to Read Next on Medscape. Related Conditions and Diseases. * ... Diffuse large B-cell non-Hodgkin lymphoma. Large cells with abundant cytoplasm and large round-ovoid nuclei with thick nuclear ... Mantle cell lymphoma. Small lymphoid cells with oval to slightly irregular nuclei and clumped chromatin and rare admixed pink ...
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory ... Leukemia/Lymphoma Phenotyping (Comprehensive-Bone Marrow). 2. Leukemia/Lymphoma Phenotyping (Comprehensive - Miscellaneous). 3 ...
... large B-cell lymphoma Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of ... Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of putative thymic ... Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell ... Olteanu H. (2018) B-Cell Lymphoma, Mediastinal, Diffuse, and Large. In: Allen T.C., Suster S. (eds) Pathology of the Pleura and ...
The proteins are markers that may help diagnose leukemia or lymphoma. ... B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B- ... B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B- ... In some cases, white blood cells are removed during a bone marrow biopsy. The sample may also be taken during a lymph node ...
... and symptoms of breast implant-associated anaplastic large cell lyphoma (ALCL). The U.S. FDA recently reported that theres an ... The cancer, known as anaplastic large cell lymphoma (or ALCL), is a rare type of non-Hodgkins lymphoma (cancer of the cells ... What is anaplastic large cell lymphoma (ALCL)?. A rare type of cancer has been reported in people with breast implants. ... Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL). *Medical Author: Melissa Conrad Stöppler, MD ...
... pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma. ... Background: Primary central nervous system lymphoma is a rare, malignant non-Hodgkin lymphoma that can arise in the brain, ... To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphoma ... Primary central nervous system lymphoma is rare, accounting for 2-6% of all primary brain neoplasms and 1-2% of all non-Hodgkin ...
... is relatively rare B-cell non-Hodgkin lymphoma that comprises 6-12% of all diffuse large B-cell lymphomas (DLBCLs) and 2-4% of ... Primary mediastinal B-cell lymphoma (PMBCL) is relatively rare B-cell non-Hodgkin lymphoma that comprises 6-12% of all diffuse ... Mediastinal gray zone lymphoma: the missing link between classic Hodgkins lymphoma and mediastinal large B-cell lymphoma. Am J ... The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and ...
For lymphomas in general, the skin is actually the second most common extranodal... ... Cutaneous T-cell lymphoma is a term that was created in 1979 at an international workshop sponsored by the National Cancer ... encoded search term (Cutaneous T-Cell Lymphoma) and Cutaneous T-Cell Lymphoma What to Read Next on Medscape. Related Conditions ... Cutaneous T-cell lymphomas are T-cell proliferative disorders. Primary cutaneous lymphomas require distinction from ...
H. D. Foss, I. Anagnostopoulos, I. Araujo et al., "Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express ... "Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?" Hematological Oncology, vol. 27, no. 4, pp. 161- ... "Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor ... "Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkins disease: evidence ...
Cutaneous B-cell lymphoma. Cutaneous B-cell lymphoma is a rare type of skin cancer that may form as a nodule that appears the ...
... page provides information about a possible association between breast implants and the development of anaplastic large cell ... lymphoma (ALCL), a rare type of non-Hodgkins lymphoma. ... Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast ... designated breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a T-cell lymphoma that can develop following ... Review data from the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and ...
Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes. We performed exome and whole-genome ... Genomic landscape of cutaneous T cell lymphoma.. Choi J1,2, Goh G3,4, Walradt T1, Hong BS1, Bunick CG1, Chen K1, Bjornson RD5, ... g) IL-2 production from Jurkat cells transduced with WT CD28 or CD28 (p.Phe51Val). Jurkat cells were stimulated with phorbol ... e-f) Binding of CD86-Fc to 293T cells stably transduced with human wild-type (WT) CD28, (e) CD28 (p.Phe51Val), or (f) CD28 (p. ...
... is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver ... Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival ... of another peripheral T-cell lymphoma, adult T-cell lymphoma. If validated, our findings would provide new insight into the ... present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas ...
... is a group of lymphomas that affect the skin. Learn about the symptoms of the different types and treatments for CTCL. ... Cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma (CTCL) is an uncommon type of non-Hodgkin lymphoma (NHL). CTCL is a cancer ... Types of cutaneous T-cell lymphoma. CTCL is not one disease. It is a group of different T-cell lymphomas that affect the skin. ... Cancer information / Cancer types / Non-Hodgkin lymphoma / Non-Hodgkin lymphoma / More types of NHL / Cutaneous T-cell lymphoma ...
NCCN Guidelines for Patients® , Mantle Cell Lymphoma. 52 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 5 Making ... At support groups, you can ask questions and hear about the experiences of other people with lymphoma. Find a support group at ...
Mantle Cell Lymphoma. 45 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 Review Treatment options for mantle cell ... If your body can endure severe side effects, you may receive immunochemotherapy followed by a stem cell transplant. During and ... lymphoma are based on the cancer stage and your health. For stage I and limited stage II cancers, options for first-line ...
Hepatosplenic T-cell lymphoma (HSTL, or HSTCL) is very rare. Sometimes it develops in people whose immune system isnt working ... Hepatosplenic T-cell lymphoma. Hepatosplenic T-cell lymphoma (HSTL, or HSTCL) is a very rare T-cell lymphoma. It may also be ... Cancer information / Cancer types / Non-Hodgkin lymphoma / Non-Hodgkin lymphoma / More types of NHL / Hepatosplenic T-cell ... Stem cell transplant. Some people with HSTL may be offered a stem cell transplant after chemotherapy. ...
The first step in treating mantle cell lymphoma is usually chemotherapy. After chemo, your doctor may recommend additional ... How is mantle cell lymphoma usually treated?. If you have mantle cell lymphoma (MCL) thats growing quickly or causing symptoms ... If you have a mantle cell lymphoma diagnosis, you might wonder what makes it different from other types of lymphoma. Learn the ... Many people with mantle cell lymphoma respond to treatment and go into remission, but the condition has high rates of relapse. ...
The Emerging Role of Immunotherapy in the Treatment of Lymphoma. *Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem ... Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Professor of Clinical ... Progress in the Treatment of Non-Hodgkin Lymphoma (NHL). * ... Update on Diffuse Large B-Cell Lymphoma. *Update on Diffuse ...
... a cancer that is a type of non-Hodgkins lymphoma, affects the white blood cells, which are cells that respond to infections in ... What Is the Prognosis for Mantle Cell Lymphoma?. A: With mantle cell lymphoma, which is a type of non-Hodgkin lymphoma, 69 ... Mantle cell lymphoma, a cancer that is a type of non-Hodgkins lymphoma, affects the white blood cells, which are cells that ... a protein which controls the growth of cells. This increase causes mantle cell lymphoma by making a particular type of B-cell ...
Its important to weigh the risks and benefits of stem cell transplantation with your doctor as you consider your treatment ... Allogeneic Stem Cell Transplantation. *Download or order The Leukemia & Lymphoma Societys free booklet, Blood and Marrow Stem ... Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ...
mantle cell lymphoma. Posted by alexandra_k on April 25, 2021, at 0:15:33 ... Re: mantle cell lymphoma alexandra_k 4/25/21. *Re: mantle cell lymphoma alexandra_k 4/26/21 ...
Patient also has a hx of non-Hodgkins lymphoma. I appreciate any ideas how t ... invasive B-cell lymphoma of L4-L5 spine. ... large B-cell lymphoma (C85.2-). mature T/NK-cell lymphomas (C84 ... Code Name: ICD-10 Code for Diffuse large B-cell lymphoma, unspecified site. Block: Diffuse large B-cell lymphoma, unspecified ... Patient also has a hx of non-Hodgkins lymphoma.. I appreciate any ideas how to code invasive B-cell lymphoma of L4-L5 spine.. ...
Low Grade B Cell Lymphoma: What Does It Mean? The diagnosis of a low grade B cell lymphoma is both a specific and a non- ... B-Cell Lymphoma Types: In-Depth List of Lymphoma Classifications A B cell is a type of lymphocyte that produces antibodies to ... Renal Lymphoma: Treatment and Prognosis This entry looks renal lymphoma, also known as primary renal lymphoma (PRL), one of the ... Reprogramming Lymphoma Cells to Respond to Therapy In a phase I clinical trial, researchers say they were able to reprogram ...
  • Mantle cell lymphoma (MCL) is a relatively rare cancer of the lymphoid cells that arises from the outer rim or mantle lymphoid follicle. (medicinenet.com)
  • What is mantle cell lymphoma (MCL)? (medicinenet.com)
  • it is termed mantle cell lymphoma because the cancer cells (lymphoma cells) arise from the outer rim or mantle of lymphoid cells that surround a lymphoid follicle. (medicinenet.com)
  • What causes mantle cell lymphoma? (medicinenet.com)
  • What are risk factors for mantle cell lymphoma? (medicinenet.com)
  • What are signs and symptoms of mantle cell lymphoma? (medicinenet.com)
  • Leukaemia Foundation: "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell Lymphoma," "Non-Hodgkin Lymphoma," "Peripheral T-cell Lymphoma. (webmd.com)
  • If you have mantle cell lymphoma, you'll likely see a variety of experts who will figure out the stage of your cancer, come up with a treatment plan, and help you manage side effects. (webmd.com)
  • A hematologist-oncologist is an expert in treating blood cancers, including mantle cell lymphoma. (webmd.com)
  • A hematologist may also be the specialist who does stem cell therapy for mantle cell lymphoma. (webmd.com)
  • This specialist will likely be the one who helps diagnose your mantle cell lymphoma by doing a lymph node biopsy -- a procedure that removes a small piece of one of these organs to check for cancer cells. (webmd.com)
  • If you've had a biopsy, they're likely the one who will look at the sample under a microscope to check for signs of mantle cell lymphoma. (webmd.com)
  • After you get a diagnosis of mantle cell lymphoma, you'll likely need a few imaging tests, such as a chest X-ray, body CT scan, PET scan, bone scan, MRI, or ultrasound. (webmd.com)
  • The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments. (news-medical.net)
  • Today's Food and Drug Administration approval of the first CAR T-cell therapy for mantle cell lymphoma represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy. (news-medical.net)
  • A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. (news-medical.net)
  • A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. (news-medical.net)
  • A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma. (news-medical.net)
  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (medscape.com)
  • 52 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 5 Making treatment decisions Deciding between options Deciding between options Deciding which option is best can be hard. (nccn.org)
  • 45 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 Review Treatment options for mantle cell lymphoma are based on the cancer stage and your health. (nccn.org)
  • What's After Chemo for Mantle Cell Lymphoma? (healthline.com)
  • How is mantle cell lymphoma usually treated? (healthline.com)
  • If you have mantle cell lymphoma (MCL) that's growing quickly or causing symptoms, your doctor will likely prescribe chemotherapy medications to treat it. (healthline.com)
  • Mantle cell lymphoma, a cancer that is a type of non-Hodgkin's lymphoma, affects the white blood cells, which are cells that respond to infections in the body, according to WebMD. (reference.com)
  • Mantle cell lymphoma is specific to the type of white blood cells called lymphocytes. (reference.com)
  • When some of the lymphocytes known as "B-cell" lymphocytes become cancerous and begin to grow uncontrollably, this is called mantle cell lymphoma. (reference.com)
  • In many cases, this happens before someone is even diagnosed with mantle cell lymphoma. (reference.com)
  • The exact cause of mantle cell lymphoma is unknown as of 2015, but it is thought that most people who contract this condition have a genetic mutation that affects the B-cell lymphocytes by triggering the release of a surplus of cyclin D1, a protein which controls the growth of cells. (reference.com)
  • This increase causes mantle cell lymphoma by making a particular type of B-cell grow uncontrollably. (reference.com)
  • What Is the Prognosis for Mantle Cell Lymphoma? (reference.com)
  • Mantle cell lymphoma (MCL) is a rare form of blood cancer belonging to the disease group classified as non-Hodgkin's lymphoma. (mdanderson.org)
  • Only 3-6% of all non-Hodgkin's lymphoma cases in the United States are mantle cell lymphoma, which forms in the lymph node region known as the mantle zone. (mdanderson.org)
  • The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. (aacr.org)
  • The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the treatment of adult patients who have mantle cell lymphoma that has progressed despite at least one prior treatment. (aacr.org)
  • Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma . (aacr.org)
  • July 24, 2020 - The U.S. Food and Drug Administration (FDA) approved the use of the chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). (lymphoma.org)
  • November 14, 2019 - The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy. (lymphoma.org)
  • October 31, 2017 - The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. (lymphoma.org)
  • October 10, 2014 - The U.S. Food and Drug Administration (FDA) approved bortezomib (Velcade) for previously untreated patients with mantle cell lymphoma. (lymphoma.org)
  • November 13, 2013 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to Ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. (lymphoma.org)
  • June 5, 2013 - The U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies. (lymphoma.org)
  • Lenalidomide currently represents the first and only oral therapy for mantle cell lymphoma, which is a rare, B-cell non-Hodgkin lymphoma. (lymphoma.org)
  • Mantle cell lymphoma comprises about five percent of all non-Hodgkin lymphomas and is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone marrow. (lymphoma.org)
  • January 23, 2012 - The U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include the subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy. (lymphoma.org)
  • Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of. (lymphomainfo.net)
  • HOUSTON - In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL). (eurekalert.org)
  • This oral inhibitor of the Bruton's tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. (eurekalert.org)
  • Mantle cell lymphoma is a particularly aggressive cancer," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. (fda.gov)
  • By the time mantle cell lymphoma is diagnosed, it usually has spread to the lymph nodes, bone marrow and other organs. (fda.gov)
  • Today's approval of Calquence was based on data from a single-arm trial that included 124 patients with mantle cell lymphoma who had received at least one prior treatment. (fda.gov)
  • The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation. (pfizer.com)
  • All registrations for the Mantle Cell Lymphoma Workshop will be reviewed and approved by the MCL Consortium Executive Committee. (lymphoma.org)
  • LRF's Mantle Cell Lymphoma Scientific Workshop, held regularly since 2003, is the Foundation's longest running scientific program, encouraging collaboration and the sharing of research developments between the world's leading MCL researchers, including LRF MCL Consortium members, MCL grantees, and scientists from the United States, Canada, and Europe. (lymphoma.org)
  • The 12th Mantle Cell Lymphoma Scientific Workshop will provide a unique forum to share scientific and clinical findings, exchange ideas, and plan new collaborations. (lymphoma.org)
  • With mantle cell lymphoma, which is a type of non-Hodgkin lymphoma, 69 percent of patients can expect to be alive five years after their diagnoses, and 59 percent are likely to be alive 10 years after their diagnoses, according to the American Cancer Society. (reference.com)
  • A micrograph of mantle cell lymphoma cells in the small intestine. (cancer.gov)
  • On October 31, the Food and Drug Administration (FDA) granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy. (cancer.gov)
  • Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that arises in B cells, a type of white blood cell. (cancer.gov)
  • Most people with mantle cell lymphoma are diagnosed with aggressive, widespread disease. (cancer.gov)
  • Unlike some other types of aggressive lymphomas, however, mantle cell lymphoma is rarely curable with current therapies. (cancer.gov)
  • In 2013, FDA approved the first BTK inhibitor, ibrutinib (Imbruvica®), for patients with relapsed or refractory (treatment-resistant) mantle cell lymphoma. (cancer.gov)
  • In other words, acalabrutinib does not appear to inhibit other tyrosine kinases that don't seem to be necessary for its action against mantle cell lymphoma. (cancer.gov)
  • FDA based its approval on data from a single-arm clinical trial of 124 patients with mantle cell lymphoma whose cancer had progressed or returned after at least one prior treatment regimen. (cancer.gov)
  • In recent years, new treatments for mantle cell lymphoma (MCL) have helped improve life expectancy and quality of life in many people with this disease. (healthline.com)
  • Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma, which has classically been considered an aggressive and incurable lymphoma. (lww.com)
  • SANTA MONICA, Calif.- Kite Pharma , a subsidiary of Gilead Sciences, Inc ., announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus (brexucabtagene autoleucel), reportedly the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). (drugdiscoverynews.com)
  • MCL is a rare form of non-Hodgkin lymphoma that arises from cells originating in the "mantle zone" of the lymph node. (drugdiscoverynews.com)
  • This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease. (drugdiscoverynews.com)
  • In the past decade, researchers have made significant progress in our understanding of this disease and we have seen an increase in clinical trials for patients, which we hope will continue to improve treatment strategies and the options available to people with mantle cell lymphoma," noted Meghan Gutierrez, chief executive officer at the Lymphoma Research Foundation. (drugdiscoverynews.com)
  • Today's news builds upon this progress and provides hope to mantle cell patients and their loved ones. (drugdiscoverynews.com)
  • Our study demonstrated significant and durable clinical benefit for patients with relapsed or refractory mantle cell lymphoma for which there are no curative treatment options. (news-medical.net)
  • ZUMA-2 is the first multi-center, Phase II study of CAR T-cell therapy for relapsed/refractory mantle cell lymphoma, and these interim efficacy and safety results are encouraging," said Wang. (news-medical.net)
  • Although this study continues, our reported results, including a manageable safety profile, point to this therapy as an effective and viable option for patients with relapsed or refractory mantle cell lymphoma. (news-medical.net)
  • In a mouse model of blastoid variant mantle cell lymphoma, treatment of tumor-bearing mice with a potent NKT cell agonist, α-galactosylceramide (α-GalCer), resulted in a significant decrease in disease pathology. (mdpi.com)
  • These data demonstrate an important role for NKT cells in the immune response to an aggressive hematologic malignancy like mantle cell lymphoma. (mdpi.com)
  • CHICAGO-Temsirolimus (Torisel) prolongs progression-free survival in patients with relapsed and/or refractory mantle cell lymphoma when compared with commonly used conventional therapies, finds an international phase III trial. (cancernetwork.com)
  • At the molecular level, mantle cell lymphoma is characterized by the translocation t(11;14) that results in the over-expression of cyclin D1, and the translation of cyclin D1 mRNA is regulated by the mTOR kinase," Georg Hess, MD, PhD, said at ASCO 2008 (abstract 8513). (cancernetwork.com)
  • Patients in the trial had relapsed and/or refractory mantle cell lymphoma and had received two to seven therapies for the disease, which may have included stem cell transplantation and must have included rituximab (Rituxan), an anthracycline, and an alkylating agent, said Dr. Hess, a hematologist-oncologist at the Johannes-Gutenberg University, Mainz, Germany. (cancernetwork.com)
  • This first randomized phase III trial in mantle cell lymphoma established the concept of using this drug in this entity," Dr. Hess commented. (cancernetwork.com)
  • Chromosomal translocations involving the immunoglobulin heavy locus is a classic cytogenetic abnormality for many B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma and Burkitt's lymphoma. (wikipedia.org)
  • citation needed] In Burkitt's lymphoma and mantle cell lymphoma, the other protein in the fusion is c-myc (on chromosome 8) and cyclin D1 (on chromosome 11), respectively, which gives the fusion protein pro-proliferative ability. (wikipedia.org)
  • Four forms of anaplastic large cell lymphoma are recognized: primary systemic anaplastic lymphoma kinase (ALK)-positive ALCL, primary systemic ALK-negative ALCL, primary cutaneous ALCL, and breast implant-associated ALCL. (wikipedia.org)
  • In particular, two different entities are recognized as systemic forms, the ALK + and ALK − ALCL [ 1 , 2 , 6 ], on genetic and clinical features, the first one being characterized by the deregulated expression of chimeric proteins expressing the intracytoplasmic domain of the anaplastic lymphoma kinase ( ALK ) gene. (hindawi.com)
  • Recently, the discovery was made that ALCL is actually a combination of two different diseases and even though they look the same under the microscope, what separates the two groups is the expression of another protein called anaplastic lymphoma kinase (ALK). (lymphoma.org)
  • At least three entities of ALCL exist, with similar cellular morphology but varying clinical courses and pathology: systemic ALCL, anaplastic lymphoma kinase (ALK)-positive, systemic ALCL ALK− and primary cutaneous ALCL. (intechopen.com)
  • This was further refined in 1994 on cloning of the t(2;5)(p23;q35) translocation breakpoint product, identified as a fusion protein of Nucleophosmin 1 (NPM) and anaplastic lymphoma kinase (ALK), the latter a previously uncharacterized protein named after the disease from which it was cloned [ 6 ]. (intechopen.com)
  • This is where the lymphoma cells have a protein called anaplastic lymphoma kinase (ALK). (macmillan.org.uk)
  • This chromosomal translocation induces the formation of the chimeric protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), which possesses significant oncogenic potential resulting from the constitutive activation of the tyrosine kinase ALK. (bloodjournal.org)
  • 6 ⇓ - 8 In 1994, 2 independent groups cloned the genes involved in this translocation and illustrated the fusion of the nucleophosmin ( NPM ) gene on chromosome 5q35 to the previously unidentified gene anaplastic lymphoma kinase ( ALK ) gene on 2p23. (bloodjournal.org)
  • 2011). Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group Study. (springer.com)
  • Although doctors treat most lymphomas with chemotherapy without surgery, in the rare case of BIA-ALCL lymphoma, surgical removal of the implants and surrounding tissues is the most important for treatment and cure. (medicinenet.com)
  • Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. (medscape.com)
  • Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. (medscape.com)
  • Some people with HSTL may be offered a stem cell transplant after chemotherapy. (cancer.ca)
  • If you achieve remission after chemotherapy, your doctor might recommend a stem cell transplant, maintenance therapy, or both to help keep you in remission for longer. (healthline.com)
  • If you're young and fit, your doctor might recommend a stem cell transplant (SCT) after chemotherapy. (healthline.com)
  • If you undergo autologous SCT, your healthcare team will remove and freeze some of your stem cells before chemotherapy. (healthline.com)
  • After you finish chemotherapy, they'll thaw and transplant the stem cells back into your body. (healthline.com)
  • Stem cell transplants (SCTs) are sometimes used for hard-to-treat Hodgkin lymphoma , such as disease that doesn't go away completely after chemotherapy (chemo) and/or radiation or lymphoma that comes back after treatment. (cancer.org)
  • Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after high-intensity chemotherapy or radiation. (lls.org)
  • The high-conditioning regimens are meant to severely or completely impair your ability to make stem cells and you will likely experience side effects during the days you receive high-dose conditioning radiation or chemotherapy. (lls.org)
  • Chemotherapy - Medications are delivered intravenously or orally to destroy cancer cells. (moffitt.org)
  • January 27, 2015 - The U.S. Food and Drug Administration (FDA) approved a same-day delivery device for pegfilgrastim (Neulasta) for non-Hodgkin lymphoma patients who do not need to return to the clinic the day after chemotherapy. (lymphoma.org)
  • Blastic NK cell lymphoma is resistant to chemotherapy and radiotherapy. (lymphomainfo.net)
  • Steroids are drugs that are often given with chemotherapy to treat lymphomas. (macmillan.org.uk)
  • If the DLBCL doesn't respond to the initial treatment or comes back, doctors may suggest high-dose chemotherapy followed by a stem cell transplant or CAR T-cell treatment , a new immunotherapy. (healthcentral.com)
  • Chemotherapy is an important treatment for ALCL and can often get the lymphoma into remission. (macmillan.org.uk)
  • Some people have radiotherapy after chemotherapy to treat an area of lymphoma. (macmillan.org.uk)
  • The study focuses on patients with aggressive non-Hodgkin lymphoma that does not respond to chemotherapy or recurs after autologous stem cell transplant. (eurekalert.org)
  • The Seattle-based biotech company said its experimental drug for non-Hodgkin's lymphoma, pixantrone, was able to completely wipe out tumors for one-fifth of patients in a clinical trial, compared with about 6 percent who did that well on standard chemotherapy. (xconomy.com)
  • The traditional first-line therapy for aggressive non-Hodgkin's lymphoma is a combination of four chemotherapy drugs. (newswise.com)
  • But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy. (newswise.com)
  • After initial chemotherapy, those who responded were randomly assigned to receive an autologous stem cell transplant (125 patients) or to a control group of 128 patients who received three additional cycles of the R-CHOP regimen. (newswise.com)
  • An autologous stem cell transplant enables a patient to tolerate very high doses of chemotherapy and/or radiation. (newswise.com)
  • After the chemotherapy and/or radiation, these stem cells are infused back into the patient. (newswise.com)
  • Previous studies have found that patients who undergo stem cell transplants have a slightly higher risk of developing secondary cancers caused by the chemotherapy and/or radiation. (newswise.com)
  • But even if the T cell lymphoma were totally unrelated to his HIV, he still needs PCP prophylxis merely on the basis of receiving combination chemotherapy, which is itself a risk for PCP. (thebody.com)
  • Combination chemotherapy, such as CHOP, followed by stem cell transplantation. (lymphomation.org)
  • A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117. (rush.edu)
  • DIAGNOSIS.T-Cell Non Hodgkin"s Lymphoma- with a background of coeliac disease- Stage 4B with bone marrow infiltration, treated with 8 cycles of CHOP Chemotherapy from August 2010 to January 2011 ,plus 4 cycles of Intrathecal Chemotherapy. (hubpages.com)
  • The disease is generally treated with a combination of chemotherapy and immunotherapy, often accompanied by a hematopoietic stem cell transplant to restore the body's ability to form normal, healthy blood cells. (newswise.com)
  • Often a stem cell transplant procedure is used as a treatment choice when lymphoma still remains after chemotherapy or returns after treatment. (uhhospitals.org)
  • This type of treatment means our team can give higher doses of chemotherapy to fight the diseased cells because new cells will be transplanted to replace them. (uhhospitals.org)
  • Chemotherapy is often suggested for Hodgkin lymphoma treatment . (uhhospitals.org)
  • However, if the cancer does not respond to chemotherapy or returns after an initial response to therapy, a stem cell transplant may be recommended. (uhhospitals.org)
  • In most cases, treatment will involve chemotherapy for non-Hodgkin lymphoma could be accompanied by radiation therapy and/or immunotherapy. (uhhospitals.org)
  • Curcumin may improve outcome in chemotherapy-refractory Natural killer/T-cell lymphoma (NKTL). (greenmedinfo.com)
  • Also required in the diagnosis is immunophenotypic evidence that cells are T lymphocytes , such as the expression of immunologic markers CD3 or CD4 , but CD30 expression must be present in all neoplastic cells. (wikipedia.org)
  • Mayo Clinic: "Non-Hodgkin's lymphoma: Diagnosis & treatment. (webmd.com)
  • The highly aggressive nature of primary central nervous system lymphoma necessitates timely diagnosis and intervention. (medscape.com)
  • Example of mediastinal lymphoma at diagnosis. (medscape.com)
  • [ 73 ] Other conditions to consider in the differential diagnosis of cutaneous t-cell lymphoma include nonlymphomatous erythroderma and erythema neurolyticum migrans. (medscape.com)
  • Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. (medscape.com)
  • Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma," Journal of Experimental Medicine , vol. 198, no. 6, pp. 851-862, 2003. (hindawi.com)
  • At Moffitt Cancer Center, we take a comprehensive and multispecialty approach to the diagnosis and treatment of cutaneous T-cell lymphoma. (moffitt.org)
  • Information about Cutaneous T Cell Lymphoma, its diagnosis and treatment. (oncolink.org)
  • Anaplastic large cell lymphoma belongs to the T-cell lymphoma group meaning that it arises from the T-cell type lymphocytes and is considered to be an aggressive lymphoma, so treatment is required upon diagnosis. (lymphoma.org)
  • These lymphomas usually presents at diagnosis in stage III or IV, and often has an aggressive clinical course requiring prompt treatment. (lymphomation.org)
  • Diagnosis requires analysis of tissue sample using a variety of tests to identify the cell type. (lymphomation.org)
  • Each lymphoma is unique and the prognosis can depend on many clinical factors, including the unique molecular and biological characteristics of the tumor, the patient's age, general health and immune status, areas of involvement, how widespread the disease is at diagnosis (stage), and if so-called b-symptoms are present. (lymphomation.org)
  • For many B-cell lymphomas, reproducible immunophenotypic patterns and cytogenetic features allow for an algorithmic approach to diagnosis. (lymphomation.org)
  • The distal duodenal and resection was sent for Histology which revealed enteropathy-associated T-Cell Non Hodgkin"s Lymphoma prior to the diagnosis. (hubpages.com)
  • The final histopathologic diagnosis was that of a CD30-positive lymphoproliferative disorder according to the WHO classification, the differential including anaplastic large cell lymphoma (ALCL) and LyP. (thefreedictionary.com)
  • With the experience and expertise of an entire team of University Hospitals Seidman Cancer Center lymphoma specialists, we are able to determine optimal treatment for your lymphoma diagnosis. (uhhospitals.org)
  • Most importantly, as a comprehensive cancer center, we have the experience with the most complex forms of lymphoma and the management of every step of care from diagnosis through treatment and on to recovery. (uhhospitals.org)
  • A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. (springer.com)
  • Primary mediastinal B-cell lymphoma (PMBCL) is relatively rare B-cell non-Hodgkin lymphoma that comprises 6-12% of all diffuse large B-cell lymphomas (DLBCLs) and 2-4% of all non-Hodgkin lymphomas. (medscape.com)
  • Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. (medscape.com)
  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. (medscape.com)
  • BCL6 causes the majority of diffuse large B cell lymphomas, the most common form of non-Hodgkin lymphoma. (redorbit.com)
  • Currently, about 60 percent of diffuse large B cell lymphomas can be cured with chemo-immunotherapy, said Dr. Melnick. (redorbit.com)
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). (rarediseases.org)
  • We report on a 60-year-old man, having angioimmunoblastic T-cell lymphoma (AITL) with aberrant expression of CD20. (nii.ac.jp)
  • Two of the ALCL subtypes are systemic lymphomas, in that they usually present with enlarged lymph nodes in multiple regions of the body, or with tumors outside the lymph nodes (extranodal) such as bone, intestine, muscle, liver, or spleen. (wikipedia.org)
  • Cancer.Net: "Lymphoma - Non-Hodgkin: Subtypes. (webmd.com)
  • A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. (medscape.com)
  • NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. (medscape.com)
  • NEW YORK (GenomeWeb) - A team from the US and Germany has uncovered new diffuse large B cell lymphoma (DLBCL) subtypes through a multi-omic analysis of hundreds of primary DLBCL tumors, including subtypes with apparent ties to DLBCL development and outcomes. (genomeweb.com)
  • In some aggressive subtypes of CTCLs, such as primary cutaneous gamma/delta T-cell lymphoma and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, more aggressive treatment including bone marrow transplantation should be considered early. (frontiersin.org)
  • Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be caused by aberrant activation of a critical intracellular pathway. (wikipedia.org)
  • Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of putative thymic origin, arising in the anterior mediastinum and showing distinct clinical and pathologic features (Cazals-Hatem et al. (springer.com)
  • Gene expression studies have confirmed that PMBCL is molecularly different from DLBCL and that it may resemble Hodgkin lymphoma. (medscape.com)
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer that affects the B lymphocytes, white blood cells that make antibodies to fight infection. (healthcentral.com)
  • DLBCL occurs in both men and women although it is slightly more prevalent in men, according to the Lymphoma Research Foundation . (healthcentral.com)
  • Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). (prnewswire.com)
  • DLBCL is the most common type of non-Hodgkin lymphoma in adults. (prnewswire.com)
  • Approximately 77,000 new cases of non-Hodgkin lymphoma are diagnosed in the U.S. each year and DLBCL represents approximately one in three newly diagnosed cases. (prnewswire.com)
  • The new findings report positive results from a pre-specified interim analysis of 51 patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of non-Hodgkin lymphoma. (eurekalert.org)
  • Loss of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlated with activation of the IL-6 signaling pathway and with worse progression-free and overall survival. (jci.org)
  • A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. (lymphomation.org)
  • What is diffuse large B-cell lymphoma (DLBCL)? (leukaemia.org.au)
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that develops from the B-cells in the lymphatic system. (leukaemia.org.au)
  • DLBCL is the most common subtype of non-Hodgkin lymphoma accounting for 30%-40% of all cases. (leukaemia.org.au)
  • This type of DLBCL has all three types of cells present- T-cells, histiocytes and large B-cells, when viewing a biopsy specimen under the microscope.Symptoms include swollen lymph nodes, fever and swelling of the liver or spleen. (leukaemia.org.au)
  • DLBCL can also be found in many other areas including the salivary glands, nasal sinuses, liver, lungs, testes, skin, brain or eye with symptoms being directly related to the amount of pressure the lymphoma is putting on the particular body part that is affected. (leukaemia.org.au)
  • DLBCL may develop independently or in some instances may develop in people who have been diagnosed with a low-grade lymphoma in the past (i.e. low-grade lymphoma can transform to DLBCL). (leukaemia.org.au)
  • The paracaspase MALT1 plays an essential role in activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) downstream of B cell and TLR pathway genes mutated in these tumors. (jci.org)
  • We confirmed that MALT1 targeting with compound 3 is effective at suppressing ABC DLBCL cells in vitro and in vivo. (jci.org)
  • Compound 3 revealed insights into the biology of MALT1 in ABC DLBCL, such as the role of MALT1 in driving JAK/STAT signaling and suppressing the type I IFN response and MHC class II expression, suggesting that MALT1 inhibition could prime lymphomas for immune recognition by cytotoxic immune cells. (jci.org)
  • Dr. Melnick's group showed that the BCL6 inhibitor was specific for BCL6 and did not block other master regulators, and that the experimental drug could powerfully kill DLBCL cells derived from human patients with this disease. (scienceblog.com)
  • Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. (medscape.com)
  • Follicular lymphoma international prognostic index. (medscape.com)
  • What Are the Symptoms of Grade 1 Follicular Lymphoma? (reference.com)
  • CAR T cell therapy is commonly used to treat large B-cell lymphoma and follicular lymphoma, which are types of non-Hodgkin lymphomas, and ongoing research focuses on minimizing toxicities and improving effectiveness, leading to better therapeutic outcomes for patients. (mdanderson.org)
  • Data from the Phase I ALPHA clinical trial found that conditioning with ALLO-647, an anti-CD52 monoclonal antibody, followed by treatment with ALLO-501, an allogeneic anti-CD19 CAR T cell product, is safe and potentially effective against relapsed or refractory large B-cell lymphoma and follicular lymphoma. (mdanderson.org)
  • Given the indolent nature of follicular lymphomas, very long-term follow-up is needed to adequately assess the efficacy of dose-intensive therapy. (nature.com)
  • In follicular lymphoma, the fused protein is Bcl-2 (on chromosome 18), which gives the fusion protein anti-apoptotic abilities. (wikipedia.org)
  • Anaplastic large-cell lymphoma ( ALCL ) is a form of cancer. (wikipedia.org)
  • The term anaplastic large-cell lymphoma (ALCL) encompasses at least four different clinical entities with the same name, which on histological examination share the presence of large pleomorphic cells that express CD30 and T-cell markers. (wikipedia.org)
  • Two types of ALCL present as systemic disease and are considered as aggressive lymphomas , while two types present as localized disease and may progress locally. (wikipedia.org)
  • This is known as breast implant associated anaplastic large cell lymphoma, or BIA-ALCL. (wikipedia.org)
  • What is anaplastic large cell lymphoma (ALCL)? (medicinenet.com)
  • The cancer , known as anaplastic large cell lymphoma (or ALCL), is a rare type of non-Hodgkin's lymphoma ( cancer of the cells that make up the immune system). (medicinenet.com)
  • The cancer is called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (medicinenet.com)
  • ALCL is a cancer of the T lymphocytes of the immune system, whereas most lymphomas that arise in the breast in people without implants are of the B lymphocyte type. (medicinenet.com)
  • Breast Implants: Update - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). (medicinenet.com)
  • The authors revise the concept of anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classification of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. (hindawi.com)
  • Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell-derived malignancy, representing around 2%-3% of all lymphoid neoplasms, according to the World Health Organization (WHO) estimates [ 1 , 2 ]. (hindawi.com)
  • According to the WHO classification, ALCL is not sustained by a unique histotype but actually includes five morphologic variants (common, giant cell-rich, lympho-histiocytic, small-cell type, and Hodgkin-like) [ 1 , 2 , 13 , 14 ]. (hindawi.com)
  • Individuals with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. (fda.gov)
  • BIA-ALCL is not breast cancer-it is a type of non-Hodgkin's lymphoma (cancer of the immune system). (fda.gov)
  • In 2011, the FDA identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL). (fda.gov)
  • designated breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a T-cell lymphoma that can develop following breast implants. (fda.gov)
  • recognized breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a unique form of ALCL that can develop following breast implant, implantation. (fda.gov)
  • Primary cutaneous anaplastic large cell lymphoma (ALCL) is slow growing (indolent). (cancer.ca)
  • Anaplastic large cell lymphoma (ALCL) is a rare aggressive T-cell lymphoma comprising only about 3 percent of all lymphomas in adults and between 10 percent and 30 percent of all lymphomas in children and can present in either the systemic or cutaneous form. (lymphoma.org)
  • Anaplastic large cell lymphoma (ALCL) is a rare type of aggressive T-cell lymphoma that is characterized by a unique appearance under the microscope. (lymphoma.org)
  • Generally, ALCL presents with symptoms typical for aggressive lymphomas, or what we call B symptoms or constitutional symptoms, that include weight loss, significant sweats at nighttime and unexplained fevers. (lymphoma.org)
  • Anaplastic large cell lymphoma (ALCL) describes a distinct group of T cell lymphomas characterised by cell surface expression of CD30. (intechopen.com)
  • Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a CD30-positive (or ki-1+) histiocytic lymphoma, later re-classified as a distinct clinical entity, ALCL [ 1 ]. (intechopen.com)
  • As well as systemic forms of the disease, there exists a cutaneous type belonging to the class of primary cutaneous CD30-positive T cell lymphoproliferative disorders-primary cutaneous (pc) ALCL [ 7 ]. (intechopen.com)
  • Anaplastic large cell lymphoma (ALCL) is a rare type of fast-growing non-Hodgkin lymphoma (NHL) . (macmillan.org.uk)
  • ALCL is a high-grade lymphoma. (macmillan.org.uk)
  • Stem cell transplants are sometimes used if there are still signs of ALCL or it comes back after other treatments. (macmillan.org.uk)
  • Anaplastic large-cell lymphoma (ALCL) was initially recognized on the basis of morphologic features and the consistent expression of CD30. (bloodjournal.org)
  • Anaplastic large-cell lymphoma (ALCL) is a relatively uncommon tumor. (bloodjournal.org)
  • 2 Subsequent immunophenotyping and gene rearrangement studies showed that the vast majority of ALCL tumors are derived from lymphoid cells of T or null immunophenotype. (bloodjournal.org)
  • Systemic ALCL comprises 2% to 8% of non-Hodgkin lymphomas in adults and 10% to 15% of these lymphomas in children. (bloodjournal.org)
  • 5 The frequency of ALCL increases to 30% to 40% of non-Hodgkin lymphomas in children when only cases with large-cell morphology are included. (bloodjournal.org)
  • Six of the British women developed breast implant-associated anaplastic large cell lymphoma , (BIA-ALCL), a rare blood cancerthat has been linked to textured implants. (thefreedictionary.com)
  • Breast implantation surgery increases the probability of being diagnosed with anaplastic large cell lymphoma (ALCL). (thefreedictionary.com)
  • At first, the study was designed to investigate the incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (thefreedictionary.com)
  • Of the large-cell T-cell lymphomas , it has the best prognosis. (wikipedia.org)
  • American Cancer Society: "Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma," "Tests for Non-Hodgkin Lymphoma," "Treating B-Cell Non-Hodgkin Lymphoma," "Types of B-Cell Lymphoma," "Types of T-Cell Lymphoma," "What is Non-Hodgkin Lymphoma? (webmd.com)
  • Primary cutaneous lymphomas require distinction from histologically similar primary nodal ones because their clinical behavior, prognosis, and therapy are often different. (medscape.com)
  • Where Can You Find Information on the Prognosis for Non-Hodgkins Lymphoma? (reference.com)
  • Information on the prognosis, or outlook, of non-Hodgkin's lymphoma is available on the website of the American Cancer Foundation. (reference.com)
  • Lymphoma in Dogs: What Is The Prognosis and Treatment? (lymphomainfo.net)
  • Patients with good prognosis potential include those under 60 years of age, those with stage 1 or 2 lymphoma, and ones whose lymphoma has not metastasized outside of the lymph nodes or has spread to only one area outside of the lymph nodes, says the American Cancer Society. (reference.com)
  • With bad prognosis factors, the patient is over age 60 and has stage 3 or 4 lymphoma, says the American Cancer Society. (reference.com)
  • Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. (wikipedia.org)
  • When a person appears to have a B-cell lymphoma, the main components of a workup (for determining the appropriate therapy and the person's prognosis) are: Establishing the precise subtype: Initially, an incisional or excisional biopsy is preferred. (wikipedia.org)
  • The most significantly enriched variants, causing p.Lys469Ter in a splice variant of POLK and p.Pro588His in PRKCB , are intriguing candidates as Polk deficient mice display a spontaneous mutator phenotype, whereas PRKCB was recently shown to be somatically mutated in 33% of another peripheral T-cell lymphoma, adult T-cell lymphoma. (springer.com)
  • What is adult T-cell lymphoma (ATLL)? (leukaemia.org.au)
  • Adult T-cell lymphoma (ATLL) is rare in countries such as Australia and North America. (leukaemia.org.au)
  • How does adult T-cell lymphoma affect the body? (leukaemia.org.au)
  • Who does adult T-cell lymphoma commonly affect? (leukaemia.org.au)
  • Do we know what causes adult T-cell lymphoma? (leukaemia.org.au)
  • How is adult T-cell lymphoma treated? (leukaemia.org.au)
  • In some cases, white blood cells are removed during a bone marrow biopsy . (medlineplus.gov)
  • Higher doses can't be used, even if they might kill more cancer cells, because they would severely damage the bone marrow, where new blood cells are made. (cancer.org)
  • This is because after getting high-dose chemo, the patient receives a transplant of blood-forming stem cells to rebuild the bone marrow. (cancer.org)
  • The blood-forming stem cells used for a transplant can come either from the blood or from the bone marrow. (cancer.org)
  • If you're considering allogeneic stem cell transplantation, you'll need a bone marrow donor. (lls.org)
  • Although the white blood cell count is usually elevated in leukemias, the hallmark of this disease is the appearance of atypical/ abnormal white blood cells in blood and bone marrow smears. (medhelp.org)
  • Stem cell transplantation - Abnormal cells in the blood and bone marrow are replaced with healthy new stem cells. (moffitt.org)
  • Your doctor may also request a bone marrow biopsy or spinal tap to determine if lymphoma cells are present in the brain or spinal cord. (healthcentral.com)
  • Stage 4 means that and the lymphoma is widespread through organs and tissues, such as the liver, lung, or bone marrow. (healthcentral.com)
  • In addition to the lymph nodes, the lymphatic system includes the spleen, which filters worn-out red blood cells and produces lymphocytes, and bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • Stiff is chair of the SWOG Bone Marrow and Stem Cell Transplantation Committee. (newswise.com)
  • So prior to treatment, stem cells are removed from the patient's blood or bone marrow. (newswise.com)
  • bone marrow and/or peripheral blood progenitor cell (PBPC) infusion on day 0). (nature.com)
  • Lymphoma is a blood cell cancer - a condition where abnormal lymphocytes (a type of white blood cell) expand in number forming tumors often in lymph nodes but also in other regions, such as the bone marrow. (lymphomation.org)
  • On the other hand, a negative FDG-PET/CT result could rule out the presence of bone marrow involvement in 90% of peripheral T-cell lymphoma cases ( Clin Lymphoma Myeloma Leuk , October 2018, Vol. 18:10, pp. 687-691). (auntminnie.com)
  • There is also some question as to whether bone marrow biopsies add any value when assessing peripheral T-cell lymphoma cases. (auntminnie.com)
  • Stem cell transplant, also known as bone marrow transplant, allows our team to bring healthy new cells to your bone marrow to enhance the production of new cells. (uhhospitals.org)
  • Chen YP, Jones D, Chen TY, Chang KC (2014) Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas. (springer.com)
  • What Are the Symptoms of Non-Hodgkin's Lymphoma? (reference.com)
  • The symptoms of non-Hodgkin's lymphoma include swollen lymph nodes, abdominal pain, fatigue, fever and weight loss, according to the Mayo Clinic. (reference.com)
  • What Are The Symptoms of Pulmonary Lymphoma? (lymphomainfo.net)
  • The symptoms of cutaneous T-cell lymphoma (CTCL) can vary depending on its stage and what form of cutaneous T-cell lymphoma is present. (moffitt.org)
  • While most skin changes are not due to cutaneous T-cell lymphoma, it's vital to rule out malignant causes and receive appropriate treatment before symptoms progress. (moffitt.org)
  • If you are experiencing possible symptoms of cutaneous T-cell lymphoma and would like to consult with a Moffitt oncologist, call us at 1-888-663-3488 or complete a new patient registration form online. (moffitt.org)
  • Lymphoma itching symptoms can range from. (lymphomainfo.net)
  • We have more information about signs and symptoms of lymphoma . (macmillan.org.uk)
  • Diffuse large B-cell lymphoma can have general NHL symptoms such as night sweats, fevers, weight loss, fatigue, loss of appetite, or shortness of breath. (healthcentral.com)
  • This painless but complex procedure treats your white blood cells and returns them to your body - which helps improve your symptoms. (rush.edu)
  • The labeling carries a boxed warning for cytokine release syndrome (CRS), which is a systemic response to the activation and proliferation of CAR T cells, causing high fever and flu-like symptoms and neurologic toxicities. (prnewswire.com)
  • We now have guidelines on how to recognize and grade these side effects and how to manage the symptoms, and we were able to implement those across multiple institutions with no prior experience with CAR T-cell therapy," said Dr. Neelapu. (eurekalert.org)
  • These symptoms are a result of the impact of the lymphoma on the nervous system. (leukaemia.org.au)
  • At UH Seidman Cancer Center, we integrate all aspects of care, including supportive care that is intended to prevent or treat infections, low blood cell counts and several symptoms caused by lymphoma. (uhhospitals.org)
  • Skin directed therapies (SDTs) serve important roles in the treatment of early stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF), as well as managing symptoms and improving quality of life of all stages. (frontiersin.org)
  • Skin directed therapies (SDTs) in cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF) serve important roles in treating disease, but also in treating symptoms. (frontiersin.org)
  • Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes. (nih.gov)
  • We performed exome and whole-genome DNA sequencing and RNA sequencing on purified CTCL and matched normal cells. (nih.gov)
  • The results implicate mutations in 17 genes in CTCL pathogenesis, including genes involved in T cell activation and apoptosis, NF-κB signaling, chromatin remodeling and DNA damage response. (nih.gov)
  • Cutaneous T-cell lymphoma (CTCL) is an uncommon type of non-Hodgkin lymphoma (NHL). (cancer.ca)
  • CTCL is a cancer that starts in mature T cells in the skin. (cancer.ca)
  • Other types of B-cell and T-cell lymphoma can affect the skin, but they are different from CTCL. (cancer.ca)
  • In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiquitously express the immunosuppressive cell surface protein CD80 (B7-1). (mendeley.com)
  • CD80 expression in CTCL cells is strictly dependent on the expression of both members of the STAT5 family, STAT5a and STAT5b, as well as their joint ability to transcriptionally activate the CD80 gene. (mendeley.com)
  • In IL-2-dependent CTCL cells, CD80 expression is induced by the cytokine in a Jak1/3- and STAT5a/b-dependent manner, whereas in the CTCL cells with constitutive STAT5 activation, CD80 expression is also STAT5a/b dependent but is independent of Jak activity. (mendeley.com)
  • Although depletion of CD80 expression does not affect the proliferation rate and viability of CTCL cells, induced expression of the cell-inhibitory receptor of CD80, CD152 (CTLA-4), impairs growth of the cells. (mendeley.com)
  • Coculture of CTCL cells with normal T lymphocytes consisting of both CD4(+) and CD8(+) populations or the CD4(+) subset alone, transfected with CD152 mRNA, inhibits proliferation of normal T cells in a CD152- and CD80-dependent manner. (mendeley.com)
  • These data identify a new mechanism of immune evasion in CTCL and suggest that the CD80-CD152 axis may become a therapeutic target in this type of lymphoma. (mendeley.com)
  • When you have a rare cancer like cutaneous T-cell lymphoma (CTCL), our experienced team has the expertise you need. (rush.edu)
  • Dermatology and cancer experts at Rush specialize in diagnosing and treating cutaneous T-cell lymphoma (CTCL) - a group of rare, non-Hodgkin lymphomas that start on your skin. (rush.edu)
  • A small group of patients (10) with cutaneous T-cell lymphoma lesions (CTCL), who had tried anywhere from two to 10 medications unsuccessfully, experienced lesion healing with a low incidence of side effects from 0.03% topical resiquimod gel in a phase I open-label clinical trial , according to Alain H. Rook, MD , of the Abramson Cancer Center at the University of Pennsylvania, in Philadelphia, and colleagues. (medpagetoday.com)
  • Micrograph of a primary mediastinal large B-cell lymphoma , a type of large-cell lymphoma. (wikipedia.org)
  • Macmillan Cancer Support: "Primary mediastinal large B-cell lymphoma. (webmd.com)
  • 1996). Primary mediastinal large B-cell lymphoma. (springer.com)
  • 2006). Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. (springer.com)
  • The molecular pathogenesis of primary mediastinal large B-cell lymphoma. (springer.com)
  • Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. (medscape.com)
  • van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. (medscape.com)
  • mediastinal (thymic) large B-cell lymphoma (C85.2-) mature T/NK-cell lymphomas (C84. (aapc.com)
  • MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma," International Journal of Radiation Oncology Biology Physics , vol. 72, no. 4, pp. 1154-1160, 2008. (hindawi.com)
  • Primary mediastinal large B-cell lymphoma outcome may be significantly improved by the addition of rituximab to dose-adjusted (DA)-EPOCH and obviates the need for radiation: results from a prospective study for 44 patients," Blood , vol. 108, Abstract 209, 2006. (hindawi.com)
  • Primary mediastinal large B-cell lymphoma: accounts for 2-4% of all non-Hodgkin lymphomas. (leukaemia.org.au)
  • have coined a 'thoracic sandwich sign' in reference to anterior-mediastinal lymphadenopathy encompassing the brachiocephalic vein on chest CT in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • This intracellular signaling pathway involved in B-cell activation and proliferation stays constantly activated, driving lymphocytes to proliferate continuously. (wikipedia.org)
  • The inhibition of this pathway can be induced by a drug known as NEMO Binding Domain, or NBD, a peptide causing increased cell death of malignant lymphocytes. (wikipedia.org)
  • It is a type of non-Hodgkin lymphoma involving aberrant T cells or null lymphocytes . (wikipedia.org)
  • B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B-lymphocytes. (medlineplus.gov)
  • A type of lymphoma (cancer of the lymphatic system) that starts in the B lymphocytes (B cells). (nih.gov)
  • One goal of allogeneic stem cell transplant is to cause the T lymphocytes in the donor's blood or marrow to take hold (engraft) and grow in the patient's marrow. (lls.org)
  • Sometimes the T lymphocytes attack the cancer cells. (lls.org)
  • Unfortunately, T lymphocytes are the same cells that cause graft versus host disease (GVHD) . (lls.org)
  • Because of this serious and sometimes life-threatening side effect, doctors in certain cases want to decrease the number of T lymphocytes to be infused with the stem cells. (lls.org)
  • The technique involves treating the stem cells collected for transplant with agents that reduce the number of T lymphocytes. (lls.org)
  • Stem cell selection is another technique being studied in clinical trials that can reduce the number of T lymphocytes that a patient receives. (lls.org)
  • This technique produces a large number of stem cells and fewer other cells, including T lymphocytes. (lls.org)
  • This type of cancer develops in the white blood cells called "T-lymphocytes. (moffitt.org)
  • Natural killer cells are beneficial specialized lymphocytes that attack viruses and tumor cells. (lymphomainfo.net)
  • In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. (lymphomainfo.net)
  • Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. (lymphomainfo.net)
  • It develops when B-cells (also called B-lymphocytes) become abnormal. (macmillan.org.uk)
  • Lymphomas are cancer of white blood cells (lymphocytes) and can be divided depending on the type of cells, B-lymphocytes (B-cells) or T-lymphocytes (T-cells), AITL is a T-cell lymphoma. (rarediseases.org)
  • Lymph accumulates in the tiny spaces between tissue cells and contains proteins, fats, and certain white blood cells known as lymphocytes. (rarediseases.org)
  • There are two main types of lymphocytes: B-lymphocytes (B-cells), which may produce specific antibodies to "neutralize" certain invading microorganisms, and T-lymphocytes (T-cells), which may directly destroy microorganisms or assist in the activities of other lymphocytes. (rarediseases.org)
  • Further genetic modification allowed the use of ALLO-647 to selectively prolong lymphodepletion, which is the process of reducing the number of normal lymphocytes before infusing patients with CAR T cells. (mdanderson.org)
  • Natural killer T (NKT) cells are a unique subset of CD1d-restricted T lymphocytes that express characteristics of both T cells and natural killer cells. (mdpi.com)
  • Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field. (news-medical.net)
  • As is the case with most all cancers, early detection of lymphomas leads to better outcomes and a positive quality of life. (moffitt.org)
  • B cell lymphoma is not one disease but a few dozen heterogeneous diseases, or individual cancers, that affect the b. (lymphomainfo.net)
  • Non-Hodgkin lymphomas are cancers that begin in certain cells of the immune system and can be either fast-growing (aggressive) or slow-growing. (prnewswire.com)
  • P eripheral T-cell lymphomas describes a diverse group of blood cancers that originate from T-cells, which may be at various stages of development. (lymphomation.org)
  • Kite is committed to bringing the promise of CAR T therapy to patients with hematological cancers, and as such, we are proud to launch our second cell therapy. (drugdiscoverynews.com)
  • 2. Any of various cancers characterized by the development of such tumors, especially Hodgkin lymphoma and non-Hodgkin lymphoma. (thefreedictionary.com)
  • Lymphomas are "blood cancers" in the lymph nodes. (wikipedia.org)
  • In an autologous stem cell transplant , a patient's own blood stem cells are collected several times in the weeks before treatment. (cancer.org)
  • The cells are frozen and stored while the person gets treatment (high-dose chemo and/or radiation) and then are given back into the patient's blood by an IV. (cancer.org)
  • The immune reaction, or GVHD, is treated by administering drugs to the patient after the transplant that reduce the ability of the donated immune cells to attack and injure the patient's tissues. (lls.org)
  • Immunotherapy - Genetically modified cells or man-made antibodies are introduced to the body to help the patient's immune system destroy cancer cells or slow their growth. (moffitt.org)
  • When using the international prognostic index, the factors are the patient's age, the stage of the lymphoma, whether it has metastasized beyond the lymphatic system, how well the patient is able to perform day to day activities, and the blood levels of lactate dehydrogenase, or LDH, states the American Cancer Society. (reference.com)
  • Each dose of Breyanzi is a customized treatment created using a patient's own T-cells, a type of white blood cell, to help fight the lymphoma. (prnewswire.com)
  • The patient's T-cells are collected and genetically modified to include a new gene that facilitates targeting and killing of the lymphoma cells. (prnewswire.com)
  • The infusions of T-APCs are intended to make the patient's reprogrammed cancer-fighting T cells last longer. (seattlechildrens.org)
  • The experimental therapy, KTE-C19, is designed to equip a patient's own immune cells with weapons to find and destroy cancer cells. (eurekalert.org)
  • In addition to killing cancer cells, this high-dose treatment also destroys the patient's immune system cells. (newswise.com)
  • Autologous CAR T cell therapy, in which CAR T cells are engineered from a patient's own T cells, is effective against advanced non-Hodgkin lymphomas, but often, creating the therapy can be logistically challenging. (mdanderson.org)
  • The researchers also collected data on each patient's peripheral T-cell lymphoma subtype, disease status, lactate dehydrogenase and albumin levels, and blood counts. (auntminnie.com)
  • They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. (wikipedia.org)
  • Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure. (wikipedia.org)
  • Usually, in treating Hodgkin lymphoma, an allogeneic transplant is used only if an autologous transplant has already been tried without success. (cancer.org)
  • After the lymph nodes shrink again or the disease gets less bulky, we typically offer patients an autologous stem cell transplantation procedure and can salvage probably about 50 percent of relapsed patients. (lymphoma.org)
  • The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma. (pfizer.com)
  • One hundred and ten adult patients with non-Hodgkin's lymphoma (NHL) received an autologous hematopoietic cell transplant (ABMT) from 1988 to 1993. (nature.com)
  • The University of Pennsylvania group reported the outcomes for 38 patients with MCL aged ≥ 60 years who received R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-Hyper-CVAD with or without autologous stem cell transplantation (ASCT). (lww.com)
  • Tecartus is an autologous, anti-CD19 CAR T cell therapy. (drugdiscoverynews.com)
  • ASCT stands for autologous stem cell transplantation. (newswise.com)
  • A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group," Blood , vol. 84, no. 5, pp. 1361-1392, 1994. (hindawi.com)
  • It then became evident that the majority of these tumors are derived from lymphoid cells of T or null immunophenotype. (bloodjournal.org)
  • One classification system for lymphomas divides the diseases according to the size of the white blood cells that has turned cancerous. (wikipedia.org)
  • The classification acknowledges the recognition of large cells with pleomorphic nuclei and abundant cytoplasm. (wikipedia.org)
  • Several classification systems exist for NHL, including the Revised European American Lymphoma Classification, which is the foundation for the WHO lymphoma classification. (medicinenet.com)
  • Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. (medscape.com)
  • Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (medscape.com)
  • WHO-EORTC classification for cutaneous lymphomas. (medscape.com)
  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). (medscape.com)
  • So biologically, these are two different disorders even though both of them are grouped together into the anaplastic large cell lymphoma classification. (lymphoma.org)
  • Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center. (medscape.com)
  • National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Hodgkin Lymphoma, Version I.2018 -- December 20, 2017. (cancer.org)
  • Our nationally renowned Malignant Hematology Program and Cutaneous Oncology Program are led by medical oncologists, radiation oncologists, hematologists, pathologists and other experts who focus exclusively on lymphomas and other hematologic diseases. (moffitt.org)
  • Cancer is the result of the uncontrolled growth of abnormal cells anywhere in the body. (medicinenet.com)
  • It gets its name because the cancer cells spread out (diffuse) all over the lymph node. (webmd.com)
  • SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. (medscape.com)
  • Cutaneous B-cell lymphoma is a rare type of skin cancer that may form as a nodule that appears the same color as your skin. (mayoclinic.org)
  • The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. (lls.org)
  • The US Food and Drug Administration (FDA) has approved Beleodaq (belinostat) for people with peripheral T-cell lymphoma who did not get better after treatment with other drugs, or whose cancer came back after treatment with other drugs. (cancer.org)
  • There are many types of peripheral T-cell lymphoma, a type of lymph node cancer. (cancer.org)
  • Phototherapy - Types of ultraviolet light are used to destroy cancer cells. (moffitt.org)
  • For more information about cutaneous T-cell lymphoma, contact Moffitt Cancer Center. (moffitt.org)
  • The Lymphoma Research Foundation's mission is to eradicate lymphoma and serve those impacted by this blood cancer. (lymphoma.org)
  • Moffitt Cancer Center provides a full spectrum of diagnostics and treatment to patients with cutaneous T-cell lymphoma and other skin malignancies. (moffitt.org)
  • Another factor that distinguishes Moffitt from other lymphoma treatment providers is our ambitious research initiatives and designation as a National Cancer Institute-designated Comprehensive Cancer Center. (moffitt.org)
  • Also known as Hodgkin's disease , Hodgkin's lymphoma (HL) is a cancer of the white blood cells, or. (lymphomainfo.net)
  • Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. (redorbit.com)
  • The researchers, who published their findings in the April issue of Cancer Cell, have identified a drug that targets an oncogene known as BCL6. (redorbit.com)
  • Radiotherapy uses high-energy rays to destroy cancer cells, while doing as little harm as possible to normal cells. (macmillan.org.uk)
  • The FDA's chief cancer drug reviewer, Richard Pazdur, slammed the application in his remarks, noting that Cell Therapeutics was seeking approval on the basis of a " single, incomplete trial . (xconomy.com)
  • Cell Therapeutics took the unusual step of quoting a cancer researcher in its press release who took a critical shot at the FDA. (xconomy.com)
  • This is a sad outcome for our patients with relapsed/refractory aggressive NHL," said Dr. Stanley Marks, chief medical officer for the University of Pittsburgh Cancer Centers, in a Cell Therapeutics statement. (xconomy.com)
  • ene and cell therapies have evolved from promising concepts to practical cancer treatment regimens. (prnewswire.com)
  • T-cell immunotherapy is an experimental new cancer treatment that stimulates the immune system to fight disease. (seattlechildrens.org)
  • Patients with aggressive non-Hodgkin lymphoma have a major unmet need in terms of available therapies that can induce long-term remission, and there really has been no new treatment for these patients for over 20 years," said lead study author Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center in Houston. (eurekalert.org)
  • He said the study, called ZUMA-1, bolsters evidence from previous trials that reported sustained remission after CAR T-cell therapy with KTE-C19, a treatment in which doctors extract T cells from a patient, genetically engineer the cells with CD19 receptors to seek out cancer cells, expand the population of the engineered cells, and then infuse them back into the patient. (eurekalert.org)
  • The American Cancer Society estimates that 66,000 people will be diagnosed with non-Hodgkin's lymphoma in 2008. (xconomy.com)
  • This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. (genomeweb.com)
  • During laboratory testing, scientists may test the treatment on cancer cells grown in petri dishes or test tubes. (healthline.com)
  • Bowel Cancer Incidence increases with age and though this was well before my Lymphoma, I regarded it as a no brainer to take part. (hubpages.com)
  • Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy," said Michael Wang, M.D., professor of the Department of Lymphoma and Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and lead investigator of ZUMA-2. (drugdiscoverynews.com)
  • This may include people who have previously been treated for other forms of cancer including a low-grade lymphoma, or people who have an autoimmune disorder. (leukaemia.org.au)
  • In CAR T-cell therapy, patients' T cells are extracted through a process called leukapheresis and genetically reengineered with CAR molecules that help T cells attack cancer cells. (news-medical.net)
  • Over the following year, 89% of the patients remained free of minimal residual disease (MRD), meaning that their blood contained too few cancer cells to form any new tumors. (newswise.com)
  • Of the patients, 40% formed immune cells capable of directly attacking and killing cancer cells. (newswise.com)
  • About the Journal of Experimental Medicine The Journal of Experimental Medicine (JEM) features peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. (newswise.com)
  • Findings published in today's issue of Cancer Cell show that an experimental compound designed by a team of researchers from Weill Cornell Medical College, the University of Maryland and the Ontario Cancer Center at the University of Toronto may effectively block the cancer-causing actions of BCL6 by attaching to a critical "hot spot" on its surface, thus killing off the cancer cells. (scienceblog.com)
  • Since emerging data implicates BCL6 in other tumor types in addition to non-Hodgkin's lymphoma, it is possible that BCL6-targeted therapy could benefit many other cancer patients. (scienceblog.com)
  • Subcutaneous panniculitis-like T-cell lymphoma is a type of skin cancer localized to the adipose tissue. (patientslikeme.com)
  • The type of cancer cell and its rate of growth will determine non-Hodgkin lymphoma treatment options. (uhhospitals.org)
  • What is T-Cell Lymphoblastic Lymphoma? (lymphomainfo.net)
  • T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma . (lymphomainfo.net)
  • T-cell Lymphoblastic Lymphoma is very rare in adults and usually occurs in people under the age of 35. (patientslikeme.com)
  • Data from patients with T-cell lymphoblastic lymphoma, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • Who has T-cell lymphoblastic lymphoma on PatientsLikeMe? (patientslikeme.com)
  • L-Asparaginase-associated hyperlipidemia with hyperviscosity syndrome in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. (acronymfinder.com)
  • The 2 primary immunodeficiency patients presented a T-cell lymphoblastic lymphoma and a diffuse large B-cell lymphoma. (acronymfinder.com)
  • T-Cell Lymphoblastic Lymphoma With Coexisting Langerhans Cell Histiocytosis--Li & Borowitz) Answers to these questions will appear in the September 2001 issue. (acronymfinder.com)
  • Gene rearrangements in T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • Researchers at The Wistar Institute and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (news-medical.net)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • Longer follow-up is needed to determine durability of the responses," says lead author Sattva Neelapu, M.D. , professor of Lymphoma and Myeloma . (mdanderson.org)
  • October 5, 2018 -- Don't expect much help from FDG-PET/CT results in predicting progression-free or overall survival among patients with peripheral T-cell lymphoma, according to a study published in the October issue of Clinical Lymphoma, Myeloma and Leukemia . (auntminnie.com)
  • CD4+CD56+ hematodermic neoplasm) is an extremely rare, aggressive form of lymphoma that affects the natural killer cells of the immune system. (lymphomainfo.net)
  • Intravascular large B-cell lymphoma: extremely rare form of lymphoma. (leukaemia.org.au)
  • the change causes an overproduction of cyclin D1, a protein that stimulates tumor cell division and growth. (medicinenet.com)
  • Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. (medscape.com)
  • Together, this study identifies CD37 as a tumor suppressor that directly protects against B cell lymphomagenesis and provides a strong rationale for blocking the IL-6 pathway in patients with CD37 - B cell malignancies as a possible therapeutic intervention. (jci.org)
  • Many hematologic malignancies express CD1d molecules and co-stimulatory proteins needed to induce anti-tumor immunity by NKT cells, yet most tumors are poorly immunogenic. (mdpi.com)
  • The study, which will be published June 19 in the Journal of Experimental Medicine ( JEM ), reveals that the vaccines are a safe and effective way to induce the body's immune system to attack any tumor cells that could cause disease relapse. (newswise.com)
  • Ronald Levy and colleagues at Stanford University previously developed a tumor cell-based vaccine that prevents lymphomas from recurring in mice. (newswise.com)
  • Tumor cells isolated from the mice are loaded with CpG oligonucleotides, short fragments of DNA that mimic bacterial DNA and can prompt an immune response against the cells when they are injected back into the mice. (newswise.com)
  • In the trial, 47 MCL patients who had achieved remission through standard immune- and chemotherapies were vaccinated with their own, CpG-loaded, tumor cells. (newswise.com)
  • Overall, our data demonstrate that the addition of a CpG-activated whole cell tumor vaccination followed by adoptive transfer of vaccine-primed immune cells to the treatment of MCL is feasible, safe, and can induce immune responses that are associated with a superior clinical outcome," Levy says. (newswise.com)
  • The researchers are now considering ways to improve the immune response to tumor cell vaccination still further. (newswise.com)
  • MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. (eurekalert.org)
  • Is there new research in clinical studies for this subtype of non-Hodgkin lymphoma? (lymphoma.org)
  • MCL is an aggressive B-cell type of non-Hodgkin's lymphoma , and the rare disease accounts for about 2%-10% of non-Hodgkin's lymphomas . (medicinenet.com)
  • Diffuse B-cell lymphoma is a type of non-Hodgkin's lymphoma. (webmd.com)
  • International Non-Hodgkin's Lymphoma Prognostic Factors Project. (medscape.com)
  • A predictive model for aggressive non-Hodgkin's lymphoma. (medscape.com)
  • Patient also has a hx of non-Hodgkin's lymphoma. (aapc.com)
  • October 19, 2012 - The U.S. Food and Drug Administration (FDA) approved a 90-minute infusion for rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkin's lymphoma (NHL) who did not experience a grade 3 or 4 infusion-related adverse reaction during Cycle 1. (lymphoma.org)
  • SupportGroups.com builds awareness and support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma . (lymphomainfo.net)
  • In non-Hodgkin's lymphoma , you have your B-cell lymphomas and you have your T-cell lymphomas. (lymphomainfo.net)
  • It is the most common type of non-Hodgkin's lymphoma (NHL), comprising up to one-third of new NHL diagnoses in the United States. (healthcentral.com)
  • The agency said that if Cell Therapeutics wants clearance to start marketing pixantrone (Pixuvri) in the U.S. for patients with non-Hodgkin's lymphoma, it will need to run another clinical trial to prove it is safe and effective. (xconomy.com)
  • I was disappointed that an agency charged with providing treatment hope for patients with life threatening diseases like relapsed/refractory non-Hodgkin's lymphoma would ignore clinically meaningful improvements in overall response rate and progression-free survival, let alone complete responses, something we all wish for our patients, but with existing treatments rarely achieve. (xconomy.com)
  • Newswise - MAYWOOD, Ill. - Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. (newswise.com)
  • Low incidence - approximately 10-15% of non-Hodgkin's lymphoma. (lymphomation.org)
  • Also, Wright has experience of cGMP manufacture of 25 ADC projects, including the manufacture of ADCETRIS (brentuximab vedotin), a CD30-targeting ADC for the treatment of relapsed or refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma , which was one of the first ADCs approved. (thefreedictionary.com)
  • NEW YORK (April 13, 2010) - Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma. (scienceblog.com)
  • They represent the commonest type of T-cell lymphomas in adults and the second most common form of extranodal non-Hodgkin's lymphoma. (frontiersin.org)
  • citation needed] Classic Hodgkin's lymphoma and nodular lymphocyte predominant Hodgkin's lymphoma are now considered forms of B-cell lymphoma. (wikipedia.org)
  • Lymphoma Research Foundation: "Peripheral T-Cell Lymphoma," "Understanding Non-Hodgkin Lymphoma. (webmd.com)
  • Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. (medscape.com)
  • Hodgkin lymphoma. (medlineplus.gov)
  • Primary central nervous system lymphoma is a rare, malignant non-Hodgkin lymphoma that can arise in the brain, spinal cord, eye, leptomeninges, or cranial nerves. (medscape.com)
  • For patient education information, see Non-Hodgkin Lymphoma . (medscape.com)
  • This is the most common type of transplant for Hodgkin lymphoma. (cancer.org)
  • Chapter 105: Hodgkin lymphoma. (cancer.org)
  • Hodgkin lymphoma: A review and update on recent progress. (cancer.org)
  • Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that is also known as "cutaneous lymphoma" or "lymphoma of the skin. (moffitt.org)
  • Cutaneous T-cell lymphoma is a form of non-Hodgkin lymphoma that affects the skin. (moffitt.org)
  • Nodal marginal zone lymphoma (NMZL) is a slow growing, type of non-Hodgkin lymphoma (NHL) . (macmillan.org.uk)
  • We have more information about causes and risk factors for non-Hodgkin lymphoma . (macmillan.org.uk)
  • You can read more about further tests you may have in our information about non-Hodgkin lymphoma . (macmillan.org.uk)
  • We have more information about staging and grading of non-Hodgkin lymphoma . (macmillan.org.uk)
  • T-cell lymphoma describes several different types of Non-Hodgkin lymphoma which affect T cells . (bionity.com)
  • Adult T-cell leukaemia/lymphoma (ATLL) is a potentially aggressive type of mature T-cell non-Hodgkin lymphoma. (leukaemia.org.au)
  • San Diego, December 6, 2016) - A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. (eurekalert.org)
  • Worldwide, B cell non-Hodgkin lymphoma is the most common hematological malignancy and represents a substantial clinical problem. (jci.org)
  • 1 The Ki-1 monoclonal antibody was originally described by the same group and was used to identify a novel antigen in the Hodgkin lymphoma cell line L428. (bloodjournal.org)
  • 2,3 Responses in B-cell non-Hodgkin lymphoma (B-NHL) were also favorable, though not as promising, with a response rate of 44 percent across a variety of different diseases. (hematology.org)
  • This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (mynewsdesk.com)
  • It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. (mynewsdesk.com)
  • MCL is an aggressive form of non-Hodgkin lymphoma in which white blood cells known as B cells become cancerous and form tumors in the lymph nodes and other parts of the body. (newswise.com)
  • Our multidisciplinary team approach, rapidly growing stem cell transplant program, wide range of clinical trials, personalized care and comforting environment ensure that patients with Hodgkin and non-Hodgkin lymphoma receive the highest quality of care. (uhhospitals.org)
  • For more information on Hodgkin and Non-Hodgkin lymphoma or to schedule an appointment with our team of lymphoma specialists, contact us today. (uhhospitals.org)
  • In MeSH, the phrase "mixed-cell lymphoma" is currently classified under non-Hodgkin lymphoma. (wikipedia.org)
  • Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. (medscape.com)
  • Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. (medscape.com)
  • Novel treatment approaches for cutaneous T-cell lymphoma. (medscape.com)
  • Herrmann JJ, Roenigk HH Jr, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. (medscape.com)
  • Cutaneous T cell lymphoma: update of treatment. (medscape.com)
  • Topical treatment of early cutaneous T-cell lymphoma. (medscape.com)
  • Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment for select patients with CML at this time. (lls.org)
  • A stem cell transplant is a complex treatment that can cause life-threatening side effects. (cancer.org)
  • The approval was based on a study of 129 people with peripheral T-cell lymphoma that did not improve with treatment or came back after treatment. (cancer.org)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • However, reduced intensity allogeneic stem cell transplants may be an appropriate treatment for some older or sicker patients. (lls.org)
  • This is the first CAR T cell therapy approved for the treatment of MCL. (lymphoma.org)
  • March 30, 2016 - The U.S. Food and Drug Administration approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). (lymphoma.org)
  • For most people with NMZL, the aim of treatment is to get rid of as much of the lymphoma as possible. (macmillan.org.uk)
  • Novartis' Afinitor was granted FDA orphan designation as a treatment of diffuse large B-cell lymphoma, according to a post to the regulator's website. (yahoo.com)
  • Note that this phase I trial suggests that resiquimod, a TLR-7/8 agonist, may aid in the treatment of cutaneous T-cell lymphoma. (medpagetoday.com)
  • SILVER SPRING, Md. , Feb. 5, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. (prnewswire.com)
  • Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma. (prnewswire.com)
  • The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma. (eurekalert.org)
  • Researchers said the results are encouraging from an efficacy standpoint and also show that CAR T-cell manufacturing, treatment logistics, and the management of adverse events can be successfully implemented across multiple sites. (eurekalert.org)
  • The stem cells develop into new immune cells, replacing the immune cells destroyed by the treatment. (newswise.com)
  • 4 Venetoclax has thus expanded the effective treatment options for patients with CLL and MCL who have exhausted other therapies including inhibition of the B-cell receptor pathway. (hematology.org)
  • Patients whose disease progresses despite treatment with the standard therapy, Bruton's tyrosine kinase inhibitor (BTKi) agents, generally do not live past six months, and few patients qualify to proceed to an allogeneic stem cell transplant. (news-medical.net)
  • C ) Cell-based reporter assay showing inhibition of cellular MALT1 activity in Raji MALT1-GloSensor cells following treatment with different inhibitors, as in Figure 1 . (jci.org)
  • Therefore, Gurion and colleagues set out to evaluate the extent to which FDG avidity could predict treatment response in patients with peripheral T-cell lymphoma. (auntminnie.com)
  • Including access to lymphoma-specific clinical trials, we offer treatment solutions such as stem cell transplants that are not always available elsewhere. (uhhospitals.org)
  • The treatment of lymphoma depends on the type of lymphoma, stage of lymphoma, age and medical history of a patient. (uhhospitals.org)
  • As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. (wikipedia.org)
  • FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. (medscape.com)
  • Only about 3 percent of all lymphomas in adults represent anaplastic lymphoma. (lymphoma.org)
  • The safety and efficacy of Breyanzi were established in a multicenter clinical trial of more than 250 adults with refractory or relapsed large B-cell lymphoma. (prnewswire.com)
  • Seattle Children's doctors and researchers are leading efforts to better treat leukemia and lymphoma in children and young adults by boosting the immune system. (seattlechildrens.org)
  • Food and Drug Administration-authorized trials at Seattle Children's are testing T-cell therapy in children and young adults with relapsed or refractory acute leukemia or lymphoma who are not likely to survive with current treatments. (seattlechildrens.org)
  • Is T-cell therapy safe to give to children and young adults with relapsed or refractory acute leukemia or lymphoma? (seattlechildrens.org)
  • These will be given to children and young adults after they receive their initial CAR T-cell therapy. (seattlechildrens.org)
  • See lymphatic system and Lymphoma Simplified . (lymphomation.org)
  • Cutaneous T-cell lymphomas comprise a group of lymphatic malignancies that occur primarily in the skin. (frontiersin.org)
  • If your body can endure severe side effects, you may receive immunochemotherapy followed by a stem cell transplant. (nccn.org)
  • Am I a good candidate for a stem cell transplant? (healthline.com)
  • Which type of stem cell transplant should I consider? (healthline.com)
  • If you go through allogeneic SCT, your healthcare team will give you stem cells from another person. (healthline.com)
  • A stem cell transplant lets doctors give higher doses of chemo (sometimes along with radiation therapy). (cancer.org)
  • Today, most transplants are done with cells that are taken out of the blood and are called peripheral stem cell transplants . (cancer.org)
  • There are 2 main types of stem cell transplants. (cancer.org)
  • They use different sources of blood-forming stem cells. (cancer.org)
  • In an allogeneic stem cell transplant , the blood stem cells come from someone else. (cancer.org)
  • Allogeneic stem cell transplantation can be a high-risk procedure. (lls.org)
  • Allogeneic stem cell transplants for patients who are older or have overall poor health are relatively uncommon. (lls.org)
  • Because of specific features on the outer coat of stem cells, doctors can selectively remove stem cells from a cell mixture. (lls.org)
  • The Wnt pathway plays a role in embryonic development, stem cell growth and tumorigenesis. (ebi.ac.uk)
  • Stem cell transplants are intensive treatments, so it is not suitable for everyone. (macmillan.org.uk)
  • The study was designed to determine whether doing an early stem cell transplant - without first waiting to see whether a patient relapses -- would increase survival. (newswise.com)
  • This is probably because patients in the control group who relapsed were later offered stem cell transplants, Stiff and colleagues wrote. (newswise.com)
  • But while stem cell transplants did not improve overall survival among the entire group of high-risk and high-intermediate risk patients, the subset of high risk patients did appear to receive both a remission and survival benefit. (newswise.com)
  • Stem cell transplants may be offered if this type of lymphoma relapses. (leukaemia.org.au)
  • Stem cell transplantation may also be an option for some people. (leukaemia.org.au)
  • Guided by these preclinical results, we designed a phase I/II clinical trial ( NCT00490529 ) to evaluate the therapeutic potential of a similar vaccination approach as an additive to standard stem cell transplantation for patients with MCL," Levy says. (newswise.com)
  • The patients' immune cells were then collected and saved while the patients received a stem cell transplant. (newswise.com)
  • The vaccination regimen appeared to be safe, causing no side effects beyond those normally associated with stem cell transplants. (newswise.com)
  • A stem cell transplant may be the most viable option. (uhhospitals.org)
  • citation needed] This nomenclature is derived from an older system of pathology, before technological advances allowed much more precise descriptions of the affected cancerous cells. (wikipedia.org)
  • Basically there are three large groups: the B cell, T cell, and natural killer cell tumors. (medicinenet.com)
  • In time, the cancerous cells turn into lymph node tumors. (reference.com)
  • It was first recognized by Stein et al 1 in 1985, who reported the consistent expression of the Ki-1 antigen (later designated CD30) in tumors with frequent cohesive proliferation of large pleomorphic cells. (bloodjournal.org)
  • 1. Any of various malignant tumors that arise from the lymphocytic cells of the immune system. (thefreedictionary.com)
  • The sample may also be taken during a lymph node biopsy or other biopsy when lymphoma is suspected. (medlineplus.gov)
  • The most common test for this lymphoma is to remove part or all of an enlarged lymph node (a biopsy ). (macmillan.org.uk)
  • Primary malignant lymphoma of the urinary bladder is very rare. (nih.gov)
  • The blood sample is sent to a laboratory, where a specialist checks the cell type and characteristics. (medlineplus.gov)
  • Histopathology revealed diffuse large B-cell lymphoma, non-germinal center type. (medscape.com)
  • The giant cell-rich type is characterized by several multinucleated elements, often provided with Reed-Sternberg-like features and prominent intrasinusoidal diffusion [ 1 , 5 , 15 , 16 ]. (hindawi.com)
  • (e-f) Binding of CD86-Fc to 293T cells stably transduced with human wild-type (WT) CD28, (e) CD28 (p.Phe51Val), or (f) CD28 (p.Gln77Pro). (nih.gov)
  • A B cell is a type of lymphocyte that produces antibodies to fight infections. (lymphomainfo.net)
  • This type of lymphoma is more common in men than women and often diagnosed in people in their 60s and 70s, according to federal statistics. (aacr.org)
  • A lab technician examines the surface of the sample tissue cells to identify the proteins that give everyone his or her own unique tissue type, called human leukocyte antigens (HLAs). (lls.org)
  • This type of lymphoma affects mostly elderly patients, and only a few cases are documented each year. (lymphomainfo.net)
  • enteropathy associated T-Cell is a type of T-Cell Lymphoma that affects the small intestine arising from T-Cellc found between the cells that line the small intestine. (hubpages.com)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • The Leukemia & Lymphoma Society. (wikipedia.org)
  • Allogeneic CAR T cell therapy, in which CAR T cells are manufactured from a healthy donor, addresses these challenges. (mdanderson.org)
  • Although early, these findings will indicate that allogeneic CAR T cell therapy can be safe and induce significant responses in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. (mdanderson.org)
  • Extracorporeal photopheresis (commonly known as ECP) is one of the most effective treatments for many people with advanced cutaneous T-cell lymphomas. (rush.edu)
  • Zolinza was evaluated in two clinical trials of 107 patients with cutaneous T-cell lymphoma who received Zolinza after their disease had recurred following other treatments. (medpagetoday.com)
  • Since 2005, LLS has funded research in Dr. Melnick's laboratory, much of which has been focused on developing better treatments for patients with B-cell lymphomas. (scienceblog.com)